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ABSTRACT 
Smart drug-design for antibody and nanomaterial-based therapies allows for optimization of 
drug efficacy and more efficient early-stage pre-clinical trials. The ideal drug must display 
maximum efficacy at target tissue sites, but to track and predict distribution to these sites, one 
must have a mechanistic understanding of the kinetics involved with the individual cells of the 
tissue itself.  This process can be tracked through biological simulations coupled with in-vitro 
approaches, which result in a rapid and efficient in-depth understanding of drug transport within 
tissue vasculature and cellular environment.  As a result, it becomes possible to predict drug 
biodistribution within live animal tissue cells without the need for animal studies.  Herein, we use 
in-vitro assays to translate transport kinetics to whole-body animal simulations to predict drug 
distribution from vasculature into individual tissue cells for the first time.  Our approach is based 
on rate constants obtained from an in-vitro assay that accounts for cell-induced degradation, 
which are translated to a complete animal simulation to predict nanomedicine biodistribution at 
the single cell level. This approach delivers predictions for therapies of varying size and type for 
multiple species of animals solely from in-vitro data. Thus, we expect this work to assist in 
refining, reducing, and replacing animal testing, while at the same time, giving scientists a new 
perspective during early stages of drug development. 
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CHAPTER I. INTRODUCTION  
Nanomedicines (NMs) like antibodies and synthetic nanomaterials are an attractive development 
to complement conventional small molecule medicines due to their active tissue targeting, 
variable circulation time, adjustable biodistribution, and added stability, all stemming from their 
inherent physical properties(1, 2).  Medical applications of these NMs as well as growing presence 
in consumer products has made these nanomaterials ubiquitous in our daily lives(3).   These 
developments both increases chance of exposure to these materials and brings the need for 
robust high-throughput methodologies to assess and quantify NM biodistribution accurately (4-6). 
Current methods to determine NM biodistribution in the blood supply often require animal sacrifice 
and tissue resection for further processing (7). This develops a severe dependence on animal 
testing, where empirical quantitative values of mass of NM per mass of tissue are obtained.  This 
approach, however, brings questions about ethics and surges in time and cost (8).  This process 
is time-consuming and requires substantial resources, as often only one time point is available 
per animal(9). Furthermore, variations in physicochemistry and the number of cells in the body 
(approximately 200 types and 3x1013 cells(10)) create an impossible workload for conventional 
quantitative histological analysis to keep up with the rapid expansion of NM usage. Moreover, 
direct in vivo tissue dose analysis may be difficult to quantify, as biological matrix 
interferences(11) may mask delivered dose to individual cells of a particular tissue(12). This 
matrix interference, as well as the destruction of tissue architecture eliminate critical knowledge 
of NM transport within the tissue cells and vasculature.   
 
Increased NM exposure poses additional risks, as biodistribution can cause toxic, innocuous, or 
therapeutic (in the case of drug development) effects, depending on cellular exposure dose at 
tissue sites. This exposure dose (or NM biodistribution) is heavily dependent on NM 
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physicochemistry(13, 14) as well as cell type(15).  “Smart nanomedicine” can be used to adjust 
physicochemical properties in order to control the dose delivered to individual target and 
peripheral tissue cells to achieve maximum efficacy and minimal toxicity during pre-clinical and 
clinical development, as well as develop products in consumer goods that may not be harmful 
upon exposure to adults or small children.  Government agencies such as the National Institutes 
of Health (NIH) and the Environmental Protection Agency (EPA) have created The National 
Nanotechnology Initiative (NNI) in 2001 as a consortium of twenty government agencies to 
improve human health and standard of life, strengthen the U.S. economy, create jobs, and support 
national defense(16). Recently, NNI members collaborated and developed a triennial strategy 
focused on betterment of these priorities. Four goals were articulated: 
1. Advance a world-class nanotechnology research and development program through, 
a. Advancing basic science and applications research 
b. Strengthening interdisciplinary research through merging various areas of science 
and technology 
c. A cultivation of new approaches that include data analytics and modeling and 
simulation 
2. Promote the transfer of new technologies into products for commercial and public benefit 
3. Advance nanotechnology through development and maintenance of educational 
resources, workforce, and toolsets and infrastructure. 
4. Support responsible development of nanotechnology 
Additionally, Nano-EHS at NIH (NIEHS) outlined a strategy(17) to establish a NM measurement 
infrastructure that produces reproducible data coupled with predictive modeling to assess human 
exposure. Concerns have also been raised by the US EPA(18) and the Food and Drug 
Administration (FDA)(19), calling for the development of new approach methodologies (NAMs) to 
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help develop and implement alternative test methods and strategies to “reduce, refine, and 
replace” vertebrate animal testing.  Thus, we cannot perform pre-clinical and clinical trials on 
every existing NM in the market on animals, so we need a way to predict and assess human safe 
exposure before running these time-consuming trials. This can be addressed through in-vitro and 
in-silico methods, which we addressed herein. This combination could direct early prioritization of 
in-vivo testing for increased efficiency and assist in understanding dosing regimens and potential 
toxic response (20). This proposed methodology can also address current guidelines for animal 
safety testing set by the International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH S5) wherein they require investigation 
of hazardous materials using minimal animal testing.  Cross-species capabilities is critical to 
capture as well as e.g. non-human primates (NHP) do not undergo dose range finding (DRF) 
studies, so it is critical to be able to predict what dose can be given to an NHP in order to deliver 
the correct quantities to a desired tissue before actually running these tests.  Thus, our work 
focuses heavily on implementation of flexible in-vitro analysis for 1) extrapolation to animal 
species with 2) cross-species capabilities.   
 
Simulation-based approaches provide a means of mechanistically tracking the transport of 
conventional small molecule drugs in human and animal tissues(21) in order to guide a more 
efficient drug development process(22).  This is feasible through physiologically based 
pharmacokinetic (PBPK) models, but their development often requires data from vertebrate 
animals for a fitted description of outcomes rather than a fully predictive approach(23).  These 
simulations, when constructed for NMs, are often descriptive of empirical animal biodistribution 
data and assume immediate diffusion of drug from blood to whole tissue based on partitioning 
coefficients, kp(24-30)  estimated from animal (in-vivo) datasets.  This assumption is not 
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descriptive of real processes involved in NM transport from the interstitial space to the cellular 
environment, as for a NM to reach the cells within a tissue, it must primarily pass through gaps 
(fenestrations) in tissue vasculature, which will vary in size and quantity depending on the tissue 
diseased state and type.  These fenestrations as well as NM physicochemistry both dictate the 
critical transport of the drug through the micro-vessel wall into infected or normal tissue cell 
environment.  This complexity is compounded due to the fact that the body is a working system 
filled with tissues of variable vasculature porosity and diameter that are highly dependent on 
diseased state and tissue type.  Furthermore, tissue cell types will all interact with the NMs 
differently, affecting delivered dose.  Thus, general tissue-blood partitioning is not sufficient to 
describe NM-biological interactions and needs substantial improvement.  Moreover, the micro 
vessel endothelial cells as well as epithelial tissue cells interact with these NMs primarily through 
active transport through endocytotic or phagocytic pathways unless they are ultra-small(31-
33)(34) (Fig. 1a).   
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Figure 1. Schematic overview of fluorescence assay. The RCF assay is coupled to an in-vitro kinetics simulation. . (a) 
Traditional partition coefficients (kp) commonly used for small molecule partitioning between blood supply and cell interior.  
For NMs, rate constants for adsorption (kad), desorption (kde), internalization (kint), and degradation (kdeg) more accurately 
represent uptake processes incident on a NM when exposed to cell environment.  (b) Layout of RCF assay, including CSI 
compartment (ratiometric standard and descriptive of cellular degradation), CKD compartment (descriptive of kinetics of NM-
cell interactions), MPE compartment, (descriptive of media degradation), and CC compartment (descriptive of control with 
cells without NM exposure). The RCF decision tree illustrates how these are connected in the assay. RCF outputs were then 
used to build a simulation (c) with parameters descriptive of adsorption, desorption, internalization, and degradation 
pathways.  Data from RCF was also (d) validated to AAS outputs. 
a 
b 
c
 
 
b 
d
 
 
b 
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Thus, the reliance of current NM PBPK models on estimation of tissue and blood kp from 
experimental animal data(27, 28, 35) make them empirically descriptive as well as eliminate the 
scientific merit of understanding what is occurring between, vasculature, interstitial space, and 
individual tissue cells, while limiting their predictive power.  These obstacles often leave scientists 
uncertain if a drug will exhibit optimal plasma pharmacokinetics, reach tissue vasculature, interact 
with epithelial tissue cells, and exhibit desirable effects in pre-clinical or human trials and has long 
been overlooked for NM development.  In order for us to truly understand and predict if a NM will 
reach cells localized within a tissue, simulations must thus be built on mechanistic fundamental 
processes involving real mechanistic transport of these materials.   
 
Current software models are still lagging with respect to tracking the mechanistic processes 
involved in transport of these materials within the tissue and blood supplies.  These simulation-
based approaches(21) have proven to be a possible solution to solve this growing problem, as 
they have proved successful for predicting biodistribution in animals for the small molecule 
market(22). Efforts have been made using simulations to account for paracellular transport 
processes through vascular reflection coefficients (σv) representative of fenestrations in 
endothelial vasculature, but are constrained by their optimization to NMs of one particular size(36-
38) , assume only two tissue pore sizes, and require fitting to animal datasets.  This impedes 
predictive capabilities, as variations in NM diameter, changes in animal species, and differences 
in tissue or diseased states can alter the vessel diameters, which then causes the reflection 
coefficient to change, thereby requiring further animal testing(39).  Moreover, the unique NM 
transport properties that dictate interactions within cells of a tissue(31-34) are currently addressed 
through time-dependent cell permeation(40) and in-vitro macrophage rate kinetics(41), but 
current simulation approaches still treat tissues as a “black box” without the critical epithelial or 
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endothelial cell content. This imposes a substantial burden for the replacement, refinement, and 
reduction of animal studies for all current NM PBPK simulations(28, 40), as running animal 
experiments for every NM type in the market for safety is not feasible(42). Some studies have, 
however, utilized in vitro assays to quantify dose-response accurately and successfully matched 
in vivo dose-response upon inhalation of NM particles(43).  To achieve in-vivo predictive 
capabilities for NMs, simulations must 1) be built from the ground-up using in-vitro methods and 
2) represent mechanistic biology involving cell-NM rate-driven transport kinetics. Such information 
is difficult to obtain with routine in-vitro techniques for high-throughput analysis(44-47), and often 
times, cell-induced degradation of the NM itself is overlooked.  Thus, a means of rapid screening 
of these materials can assist in providing an integrated high throughput approach to quantitatively 
predict NM biodistribution in preclinical and clinical species to aid in rapid NM development and 
to protect human health through estimation of exposure dose in single cells of a tissue. In-vitro 
methods could help address these knowledge gaps, but so far there exists a limited connection 
between in-vitro quantitative outputs and in-vivo biodistribution. The reason is that data obtained 
in cell and animal studies are primarily observational quantities acquired from tissue 
homogenization. Different studies also tend to be based on different methods that are difficult to 
quantitatively correlate, for example flow cytometry and atomic absorption spectroscopy (AAS). 
 
In-vitro techniques can help bridge the current knowledge gap through mechanism-based models, 
specifically assays that show translational capabilities across multiple species. However, in-vitro 
bioassay information may be difficult to translate into a context where the data can be useful for 
assessing human health.  This problem is outlined specifically in a paper published by a 
consortium of academics and industry partners (48) wherein they state that mechanism-based 
approaches can provide better information for regulatory decision-making. If in-vitro/in-silico 
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studies yield optimal dose/response profiles in-vivo, DRF studies may be minimized, which can 
reduce animal testing substantially. Delivery of NM dose to tissues occurs inside individual cells, 
which are primarily responsible for toxic response. Lack of cellular resolution thus severely 
hinders accurate prediction of biodistribution and subsequent toxic response.  In vitro dose-
response connections have been successfully extrapolated to in vivo toxicity data for the 
respiratory tract using simulations(49) through the use of the Multiple Path Particle Dosimetry 
(MPPD) model. Here, dose-response modeling successfully connected in-vitro predicted outputs 
to animal measured outputs.  However, once a NM deposits onto the respiratory tract, it will also 
absorb into the blood supply(50)  where it poses a new set of potential toxic effects on a variety 
of organs including liver and kidney(51-54) . For instance, there is evidence of human exposure 
and death due to systemically absorbed Ni-based nanoparticles post-inhalation exposure, 
including severe toxicity in kidneys (55). Such cases suggest the need for not only predicting 
deposition and delivered dose to cells of the respiratory tract, but the need to track systemic 
distribution of NMs after inhalation, oral, or intravenous exposure(56). Currently, no PBPK NM 
systemic simulation model exists for translation of systemic tissue and cell circulation to address 
this issue.   
 
Experimental results that can 1) give knowledge on particular cell uptake processes and 2) 
provide mechanistic translational cell kinetics that can be used to understand how and why a 
particular NM can get around an animal are key in connecting in-vitro data to animal 
biodistribution. Current efforts have attempted this for tissue macrophages, but are still in 
development for tissue epithelial cells(41). Tissue epithelial cells are crucial to consider, as they 
are the fundamental unit of a tissue and are responsible for the primary interactions of NM with 
whole-tissue. Currently, whole-tissues are looked at as a black box with no additional resolution, 
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which limits predictive capabilities for those performing in-vitro and in-vivo testing. A combination 
of high-throughput in-vitro methods and predictive computational models can help bridge the gap 
between in-vitro cell uptake results and in-vivo biodistribution (4, 5, 22, 57). This could provide an 
avenue towards reduction of animal testing.   
Here, we report a series of experiments to systematically and precisely predict NM biodistribution 
in multiple species of animals at the single cell level from in-vitro data alone.  Essentially, it is a 
combination of a high-throughput quantitative fluorescence in-vitro assay (Fig. 1b)  coupled with 
a cell simulation (Fig. 1c) that uses an artificial intelligence algorithm(58) to optimize rate 
constants representative of an average of individual tissue cell interactions with a NM. Our method 
quantifies the kinetics of mechanistic biological processes (adsorption to cell membrane, 
desorption from cell membrane, internalization, and degradation) for NMs with single cells to 
obtain rates quantitatively descriptive of their interaction with the cells, which we validated by 
Atomic Absorption Spectroscopy (Fig. 1d). So far, the issue of degradation on the fluorescent 
signal given off by NMs has been difficult to address when using fluorescence as a tool for uptake 
quantification in-vitro(59).  Thus, the in-vitro fluorescence assay takes into account effects of cell-
induced and media induced degradation through ratiometric analysis (ratiometric calibrated 
fluorescence, or RCF).(60) We demonstrated this capability through the use of degradable 
quantum dots (QSH)(61), and compare the results with stable dye loaded polystyrene NMs (PS-
COOH) in the first phase of experiments. To truly understand how physicochemistry can affect 
raw data obtained from the RCF assay, we studied a library of compounds with differing cores.  
Here, we answered questions on how differences in size and charge can affect uptake as well as 
if the uptake processes are primarily first order at exposure doses given in-vivo.  This is critical, 
as animal studies often utilize materials of differing 1) type, 2) charge, and 3) size, so an 
understanding of these contributions is needed in order to proceed with any assumptions made 
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herein.  Once biochemical analysis was completed for the library, the RCF assay was run to 
quantify uptake of fluorescent quantum dots (QDs)  in cells commonly encountered in living tissue 
(liver, kidney, endothelial, and macrophage).  Data from the in-vitro RCF assay fed directly to the 
cell simulation to extract rate kinetics involved in mechanistic biological processes. These kinetics 
included NM adsorption to cell membrane (kads), desorption from cell membrane (kdes), 
internalization (kint), and degradation (kdeg), which are central to cell interaction with NMs. Thus, 
the this full in-vitro/in-silico approach gives vital information on factors including 1) NM stability, 
2) quantitative kinetics of cellular uptake, and 3) localization with subcellular resolution that can 
be transferred to in-vivo simulations.  
 
The above kinetic rate constants were extracted from these NM-tissue cell interactions in-vitro 
and translated through mechanistic biology to deliver a fully predictive animal simulation of drug 
biodistribution with cellular resolution within tissues.  The in-vitro rate kinetics for an averaged 
population of tissue cells obtained from the in-vitro portion of this work were translated to 
simulations built for multiple species of animals including mice, rats, and NHP according to their 
tissue volumes, cellular content, and blood flow rates.   
 
Our approach solves problems with current in-vitro analytical approaches for quantitation of 
cellular NM content, where results are difficult to translate directly to animal studies and lack 
mechanistic perspective(44-47). We also addressed current issues with cell-induced degradation 
of NM fluorescence that is often overlooked, which can produce false negatives(59, 60).  
Validation of our in-vitro work was performed through simulated lysosomal analysis coupled with 
Atomic Absorption Spectroscopy (AAS). Lastly, our in-vivo simulation was validated against 
published whole-body animal data for rats, mice, NHP as well as single cell data.  QDs were used 
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as a model system because of their known potential in nanomedicine while also considering their 
limitations such as degradation under acidic conditions with cadmium leakage from the core. We 
show here that we are able to fully account for the complexities in such a NM platform, and we 
fully extended this capability to antibody and metal/polymer based NMs.  
 
This research significantly improves on current scientific understanding through the now ability to 
translate data from cell studies to full animal cell uptake for calculation of in vivo target cellular 
dose, with cross-species translation.  This high-throughput makes significant advancements 
toward reduction of experimental animal studies through extrapolation of in-vitro data to in-vivo 
biodistribution.  Results are obtained in minutes through optimization of software architecture on 
desktop hardware. Current evaluation of nanomaterial safety involves time consuming data 
collection and piecing together available exposure and toxicity information, and it this must be 
completed one material at a time. For many chemicals in consumer products these issues have 
been successfully addressed with software tools, but such efficient tools are still lacking for 
nanomaterials’ hazard evaluation. This in vitro to in vivo extrapolation for potential in hazard 
assessment(62) delivers true effective doses at sites of interest which benefits for those interested 
in development of therapeutics, regulation, and protection of human health in the consumer 
space. 
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CHAPTER II. IN-VITRO CELL UPTAKE ANALYSIS AND VALIDATION 
OF FLUORESCENT ASSAY 
In vitro systems are considered viable “bottom-up” approaches for identification, characterization, 
and quantification of NM interactions for a variety of tissue cell types because of their ability to 
provide data in a more controlled environment. Thus, in vitro assays can be used as benchmarks 
for prediction of animal biodistribution and subsequent toxicity.  In vitro simulation-based 
approaches exist to predict dose at target cell site for NMs (ISDD)(57), but with limitation such as 
limitations to only spherical particles, do not predict degradation of the NM upon exposure to 
cellular environment(63), and may not differentiate between internalized and membrane-bound 
particles(64), given that particles are internalized via endocytotic/phagocytic pathways(31-33)(34)  
These issues must be addressed, as supported by a recent EPA review(65), that states in vitro 
systems still require significant improvement for proper interpretation and translation of 1) dose 
and 2) response data. In some cases, doses are misinterpreted through false positives/negatives 
due to substantial NM-dye(45) or NM-biological degradative effects(66).  The result is data non-
representative of the true dose, which can be disastrous for drug development(67).  Furthermore, 
particle size can change in biological serum as well as usage of improper solvent during uptake 
experiments will often yield faulty uptake and subsequent toxicity measurements.  The EPA also 
discusses the importance of utilizing mechanistic biology in in vitro assays in order to elucidate, 
interpret, or translate to in vivo animal studies and questions current practices in relying solely on 
in vitro approaches(65). For instance, the Faustman group recently supported this by determining 
benchmark dose (BMD) from exposure dose and is the true dosimetric dose(68).  To achieve in-
vivo predictive capabilities for NMs, simulations must represent physical processes a NM 
undergoes with the animal vasculature and cells, while accounting for any significant cell-induced 
degradation that is often overlooked (12, 63, 69, 70). 
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Here, cell-NM uptake was captured through the fluorescence signal emitted by the fluorescent 
CdSe/ZnS COOH (QSH or QD) and dye-loaded carboxy-functionalized polystyrene (PS) due to 
their known degradation and stability in-vitro, respectively (71).  Hepa1-6 was chosen as the 
model cell line to demonstrate development of this fluorescent approach due to the 
aggressiveness of murine liver hepatoma (13).  We allowed cells to reach 90% confluence and 
establish membrane integrity(72) after 48 hours. Comprehensive analysis on toxicity (Appendix 
A1) and stability (Appendix A2) reveal minimal toxicity and sedimentation for a 10nM dose of the 
NMs chosen for this study, indicating minimal cell detachment and constant exposure dose.  All 
data are within the linear dynamic range, as well as within the limits of detection and quantitation 
(Appendix A3, Appendix B1). 
The RCF assay is built starting from the (schematic in Fig. 1) application of cells on a 96-well 
plate in 3 “compartments”: the Cell System Interactions (CSI) compartment (cells + NM 
(unwashed), accounts for cell-induced NM degradation), the Cell Kinetic Data (CKD) 
compartment (cells + NM (washed), measurement of NM uptake), and the Cell Control (CC) 
compartment (cells in media + no NM (unwashed), control with untreated cells to subtract 
background signal). The Media and Protein Effect (MPE) compartment (no cells + NM in media 
(unwashed)) accounts for media and protein induced degradative effects on the NM in the 
absence of exposure to cells. Note that the CSI and MPE compartments are never washed and 
therefore maintain the initial applied dose of NM (10 nM in this demonstration of the method).  The 
CKD compartment is washed at each time, t, to remove NMs that are not cell membrane bound 
or internalized by cells. Control experiments on blank wells showed minimal NM adhesion to the 
sides and surface of wells, indicating all fluorescence should strictly come from NM interacting 
with cells. For RCF assay development and validation to AAS for QSH, we used 18 wells per 
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compartment, which resulted in one 96-well plate per time point. In applications of the method, 
such a large statistical group is not required. Therefore, wells will be freed up to allow for multiple 
time points and cell types on the same plate.   
At time zero, the CSI, CKD, and MPE compartments were dosed with 10nM QSH or PS (10% 
FBS DMEM suspension), with one NM type per plate. Comparing (by t-test) the fluorescence 
signal for wells in the CSI compartment at time t with the fluorescence signal from wells in the 
MPE compartment at time t gives insight into cell-induced degradation (see Fig. 1 RCF decision 
tree). If they are statistically different we conclude cell induced NM degradation is present and the 
quantity of fluorescence signal loss due to this effect is determined from the difference of CSI and 
MPE at time t (see Fig. 2a-c).  
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Figure 2.  Fluorescence data from cell kinetic studies for 0, .5, 1, 2, 4, 6, 12, and 24 hours.  
Total fluorescence for wells with (CSI) and without (MPE) cells exposed to 10nM for (a) QSH 
and (b) PS. Fluorescent intensities ICSI,t and IMPE,t for (a) differ significantly (P<0.05) for QSH at 
approximately 4 hours, indicating cell-induced  cellular induced degradative effects.  Fluorescent 
intensities IMPE,t and IMPE,0 differ significantly from 30 minutes, indicating media degradation at 
this time. For PS (b), no significant cell induced degradation is present (P>0.05).  Media 
induced degradation begins at 6 hours (P<0.05).   Differences between ICSI,t and IMPE,t and IMPE,t 
with IMPE,0 were plotted in (b), showing a steady increase for QSH and constant intensity for PS.  
Media (Imdeg) and cell (Icdeg) induced degradative values were calculated from (a, b) and plotted 
against time in (c). Fluorescent intensities were taken after washing 2X  with complete growth 
medium and further trypsinization for (d) QSH and (e) PS. Cell fluorescence values from CKD 
(d, e) were ratiometrically used to determine concentration (nM) of QSH and PS NM 
uptake/adsorption in (f).  The ratiometric calibrated concentration of QSH (black, solid) shows 
significantly higher values (P<0.05) than raw values (black, dashed). However, PS does not 
degrade, so calibrated (blue, solid) and raw (blue, dashed) concentrations are not significantly 
different. Statistical t-test p-values are described as follows: ***P<0.001, **P<.01, and *P<0.05.  
 
Similarly, comparing the fluorescence signal (by t-test) from wells in the MPE compartment at 
time t with respect to MPE at time zero gives a description of media-induced degradation. These 
critical steps guide NM uptake calculations, especially if degradation is present.  
Fluorescence data on NM-cell total uptake (adsorbed + internalized) were obtained from the CKD 
compartment after washing 2X, trypsinizing, and mixing (Fig. 2d,e), with minimal trypsin 
a b c 
d e f 
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interference on signal found (Appendix A4).The CKD fluorescence signal at time t (ICKD,t) is 
representative of adsorbed and internalized NM. Comparison of signal obtained from CKD to CSI 
at time t (ICSI,t) for a given concentration of NM applied (nM, [Dose]) will yield the ratiometric 
calibrated concentration of NM taken up by cells ([Uptake]c,t) as follows, 
[𝑈𝑝𝑡𝑎𝑘𝑒]𝑐,𝑡  =
𝐼𝐶𝐾𝐷𝑡 
𝐼𝐶𝑆𝐼𝑡
 ∗  [𝐷𝑜𝑠𝑒]    (1) 
Here, NM located within CKD and CSI compartments have both undergone media and cell-
induced degradation. This ratiometric approach thus implicitly accounts for NM degradation 
without further data processing and requires no external calibration curve. For comparison, raw 
concentrations were obtained from the intensity of the CKD compartment at time t relative to the 
CSI compartment at time 0 (replace ICSI,t with ICSI,0 in equation 1) to understand the degradative 
effect cells and media can have on a NM. Figure 2f shows results obtained from usage of 
equation (1) for ratiometric calibrated and raw data calculations. 
To ensure repeatability, the RCF assay was completed approximately 2 months apart with a new 
batch of thawed cells for both NM types (n=2), with reproducible results (Fig. 2,  Appendix 
A5,A6).  
Comparing Results from Assay for QSH and PS 
A key consideration to make was that data from the CSI compartment in Figure 2a indicate media 
induced degradation from 30 minutes and cell induced degradation from 4 hours for QSH, while 
Figure 2b shows no cell induced degradation and minimal media induced degradation occurring 
after 6 hours for PS. This was further tested by prolonged intracellular exposure studies, which 
resulted in a continued decrease in fluorescence signal (degradation) observed for QSH QD and 
full stability for PS (Appendix A7). These results indicate that the collected fluorescence signal 
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can be sensitive to the intracellular and media environment depending on the NM studied. All 
averaged cell- and media-induced degradation values (Icdeg,t and Imdeg,t, respectively) are 
quantified in Figure 2c. Evidence of cell-induced degradation is given by lysosomal colocalization 
studies, observation of substantial Cd2+ core leakage (Appendix A8) under simulated lysosomal 
conditions (Figure 3d, top and bottom inset, respectively),(73),(74) and fluorescence data 
under cell exposure (Appendix A9) and lysosomal conditions (Appendix A10). However, our in-
vitro studies with cells also showed minimal export of free Cd2+ from cells to the supernatant 
(Appendix A11). We also noticed minimal Cd2+ induced toxicity in cell culture (Appendix A12). 
Raw fluorescence data for QSH and PS collected from the CKD compartment (Fig. 2d,e) show 
an overall increase of raw fluorescence signal over time for both NMs, but with different profiles.  
The raw QD profile rises to a maximum at approximately 12 hours, while the raw PS profile rises 
and saturates within 1 hour. Note that these raw fluorescence signals represent data that include 
degradation effects in the case of QSH.  
Application of equation 1 ensures that degradation effects are accounted for during calculation of 
NM concentrations (refer to methods for proof) since we compare ICKD,t with ICSI,t at their respective 
time points. By doing so, we internally calibrate the raw fluorescence signal collected from the 
(washed) CKD compartment to the (unwashed) CSI compartment (internal standard), knowing 
that both compartments degrade under the same conditions, and we obtain ratiometric calibrated 
NM concentrations that are independent of NM degradation. Ratiometric calibrated QSH 
concentrations (Fig. 2f) show a completely different profile from QD concentrations calculated 
based on the corresponding raw fluorescence data (for calculation, see online).  A non-saturable 
uptake is found for the ratiometric calibrated QSH concentration as a function of time with Cmax 
occurring at 24 hours (0.478  0.122 nM), and significant deviation between calibrated and raw 
profiles is observed for QSH starting from approximately 4 hours, which is when cell-induced 
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degradation begins (Fig. 2a). Raw fluorescence-based QSH concentrations (Fig. 2f) indicate 
saturable cell uptake, with maximum concentration (Cmax) occurring at approximately 12 hours 
(0.228  0.0852 nM).  In comparison, the calibrated and raw PS uptake profiles are not statistically 
different (P > 0.05), and reach saturability within 1 hour of exposure (Fig. 2f blue, solid and 
dashed).  Overall, we find a fraction of up to 4.781.22% QSH and 1.070.085% PS was 
adsorbed to/internalized by cells after 24 hours with respect to the initial applied dose.  
Atomic Absorption Spectroscopy Analysis and Validation of Assay 
AAS was run to validate the RCF assay using absolute cadmium content with respect to QSH for 
the two studies (n=2) discussed above. Samples were collected from all compartments in the 
RCF assay at each time t, degraded in 33% v/v aqua regia (AR), and measured for absolute 
cadmium content. Note that AR treatment leads to a dilution of [Dose] from 10nM to 6.66 nM that 
is accounted for in calculations (see methods).  AAS measurements were referenced to a 6-point 
cadmium calibration curve (Appendix A13) constructed with equal %v/v AR. As expected, AAS 
data obtained from the CSI and MPE compartments show that the cadmium concentration in both 
scenarios remained equal (P>0.05) at constant concentrations of approximately 3.600.0602 
mg/L and 3.540.0841 (Fig. 3a), respectively, since no cadmium is removed from the system for 
these samples (unwashed).  
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Figure 3. AAS analysis and validation to RCF method.  MPE and CSI compartments (a) contain 3.600.0403 mg/L and 
3.540.0839 mg/L cadmium concentration, respectively.  Data for CKD in (b) show gradual increase in cadmium 
concentration. Nanomolar quantities of QSH calculated from AAS and compared to fluorescence are shown in (c), with 
ratiometric calibrated fluorescence results closely matching AAS average outputs. AAS average outputs were determined 
using a serial dilution of QSH with reference to a 6-point Cd calibration curve.  (d) A two-tailed t-test p-value analysis between 
QSH concentrations adsorbed/internalized as determined by AAS, and ratiometric calibrated (dotted line) or raw (solid line) 
data from in-vitro assay accounting for or not accounting for cell-induced degradation, respectively, was performed. 
Nanomolar quantities shows increase in p-value when correcting for cell-induced degradation (calibrated). Asterisk after cell-
induced degradation implies onset of significant increase in p-value when accounting for cell induced degradation. Top inset 
shows lysosomal colocalization studies performed for QSH after cell exposure, with significant lysosomal sequestration. 
Bottom inset gives visual evidence of fluorescence loss upon exposure to lysosomal conditions. After 24 hours, a snapshot 
was taken to illustrate the diminished fluorescence due to citric acid exposure. Solutions 1-6 with equal concentrations of 
10nM QSH with varying pHs (2.5-7.4, left to right) of 25mM stock citric acid buffer solution was made in complete growth 
medium (DMEM supplemented with 10%FBS).  Solution 1, pH 2.5; Solution 2, pH 3.0; Solution 3, pH 3.5; Solution 4, pH 4.0; 
Solution 5, pH 4.5; Solution 6 pH 7.4, no citric acid.
a 
b 
c 
d 
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Parallel studies using a sample of QSH stock diluted to 6.66nM showed no significant difference 
(P>0.05, Appendix A14), indicating quantitative collection of Cd2+ from the 96-well plates (RCF 
assay).  Extraction and harvest efficiencies for each time point were also determined to 
understand if the full dose of cadmium was extracted from the cells and harvested from the wells, 
with all results showing full extraction and harvest efficiency (Appendix A15, A16).  
AAS data obtained from the CKD compartments (Fig. 3b) show a gradual increase in total Cd2+ 
content, up to an average of 0.164  0.0332mg/L, which corresponds to 4.56  0.925% of the 
applied dose. All experimental data lay significantly above both the limits of detection and 
quantitation (LOD and LOQ, respectively) with Pearson’s coefficient of 0.999 (Appendix B2). 
Using these data, cadmium concentrations from AAS were converted to nM concentrations of 
QSH through a linear correlation of the slopes of the QSH and Cd(NO3)2 AAS calibration curves 
(methods and Appendix A17). We also performed a standard additions method and 6-point 
calibration method in parallel for the 24 hour time point (Appendix A18). Results did not differ 
significantly (P>0.05, Appendix A18), indicative of minimal cell matrix interference on AAS data.  
All data in Figure 3c indicate similar QSH uptake up to 4 hours (P > 0.05, Fig. 3d) suggesting no 
significant degradation occurs.  After 4 hours, as CSI and MPE intensities in Figure 2a indicate, 
cell-induced degradation takes effect, and raw QSH concentrations obtained from the in-vitro 
assay begin to saturate and deviate from AAS as well as from the RCF-based QSH concentrations 
(Fig. 3c,d). AAS and RCF-based QSH concentration uptake profiles are equivalent for all time 
points and do not differ with statistical significance. Profiles for the ratiometric calibrated 
fluorescent concentrations match AAS, thus validating the fluorescence portion of the research 
herein.  
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Cell simulation gives insight on subcellular localization and degradative rate.  
A kinetics-based in-vitro model was built to extract rate constants for adsorption, desorption, 
internalization and degradation of both NMs from the RCF assay. This cell kinetic model was 
guided by a variety of biological processes for NM internalization including NM adhesion, 
desorption, internalization, and degradation through fist-order rate constants kads, kdes, kint, and 
kdeg. The model consists of compartments representative of 1) media 2) cell membrane and 3) 
cell space.  The cell kinetic model assumes a simple 3 compartment model, enough to provide 
sufficient understanding of whether a NM has made it inside the cell, remained outside, and how 
much it degraded.   
Media Compartment. This compartment includes the media environment from which cells receive 
their respective NM dose. The initial dose condition was taken as the 10nM applied in the RCF 
assay. The media compartment NM dose evolution with time is then described as: 
 
𝑑[𝑀𝑒𝑑]
𝑑𝑡
= −𝑘𝑎𝑑𝑠 ∗ [𝑀𝑒𝑑] + 𝑘𝑑𝑒𝑠 ∗ [𝑀𝑒𝑚]    (2) 
where [Med] is concentration (nM) of NM in media, [Mem] is the concentration (nM) of NM adhered 
to cell membrane, and kads, kdes are the first-order rate constants for adsorption and desorption to 
and from the cell membrane, respectively. 
Cell Membrane Compartment. The cell membrane compartment includes the outer portion of the 
cell with which the NM interacts.  This compartment separates the media from the internal space 
of the cell.  NMs that are internalized by the cell must first adsorb to this compartment through the 
adsorption rate constant, kads.  Once adsorbed, NMs can 1) leave this compartment through 
desorption, kdes or 2) enter the cell via kint as expressed by: 
 
𝑑[𝑀𝑒𝑚]
𝑑𝑡
= 𝑘𝑎𝑑𝑠 ∗ [𝑀𝑒𝑑] − 𝑘𝑑𝑒𝑠 ∗ [𝑀𝑒𝑚] − 𝑘𝑖𝑛𝑡 ∗ [𝑀𝑒𝑚]  (3) 
with parameters described above. 
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Cell Space Compartment. The cell space compartment receives NMs that have transported inside 
the cell via the first order rate constant for internalization (kint).  Here, NMs can become degraded 
if the process occurs (determined through RCF assay). The cell space compartment NM dose 
evolution as a function of time is then described as: 
 
 
𝑑[𝐶𝑒𝑙𝑙]
𝑑𝑡
= 𝑘𝑖𝑛𝑡 ∗ [𝑀𝑒𝑚] − 𝑘𝑑𝑒𝑔 ∗ [𝐶𝑒𝑙𝑙]     (4) 
where [Cell] is the concentration (nM) of QSH in cell interior at time t and kdeg is the first order rate 
constant for degradation of QSH obtained from optimization to raw datasets (see below).  
All above equations were fit to RCF data (QSH ratiometric calibrated, PS, i.e. degradation effects 
removed) through optimization of parameters kads, kdes, and kint.  Here, the genetic algorithm (GA), 
originally developed by Holland in the early 1970s(58) was used as an artificial intelligence 
algorithm for a robust optimization of parameters based on evolutionary ideas of natural selection. 
For optimization, initial vectors (“chromosomes”) comprised of rate constants (“genes”) were 
randomly populated by the GA, fed to the cell kinetic model, calculated for fitness, underwent 
selection, crossover, and mutations to maximize diversity and produce better fitness at each 
iteration (“generation”). At model convergence (20-50 generations, Appendix A19), the optimized 
parameters provided reasonable correlation coefficients (R = 0.994 and 0.938 at P < 0.001), 
coefficients of determination (R2 = .989 and .880), standard errors (S = 0.0152 and 0.0158nM), 
and residuals for QSH and PS respectively (Appendix B3 and Appendix A20). Next, we 
reconsidered QSH raw concentration values containing degradation effects to determine the rate 
of degradation (kdeg), holding the previously optimized adsorption, desorption, and internalization 
rates (kads, kdes, and kint) as constant. At model convergence (Appendix A21), visuals of model 
outputs show reasonable fit to measured RCF data for QSH and to raw QSH assay data with 
degradation (ratiometric calibrated and raw datasets, respectively in Fig. 4a).
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Figure 4. Outputs of cell simulation quantify rates of adsorption (kads), desorption (kdes), 
internalization (kint) and degradation (kdeg) of NMs.  (a) QSH model fits (line) to data (open 
circle) for cell samples taken from CKD for raw (blue) and calibrated (red) RCF datasets. Error 
bars indicate 95% confidence for model fit to data. (b) Model output prediction for amount of 
QSH degraded (red) and subsequent free cadmium formation (blue) predicted by model.  
Experiments with simulated lysosomal buffer  give comparable free cadmium release from 
degrading QSH (purple and orange squares). (c) Application of RCF assay and cell simulation 
to stable PS nanoparticles shows early saturation compared to QSH QDs. (d) Cell simulation 
provides data on subcellular localization of NMs from RCF datasets, showing membrane and 
internalized quantities. (e) Table summarizing kinetic rate constants obtained from FORECAST. 
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Rate constants include adsorption (kads), desorption (kdes), internalization (kint), and degradation 
(kdeg) for QSH QDs and PS NMs. (f) Confocal imaging of Hepa1-6 cells dosed with 10nM QSH 
and PS. Cells were collected from RCF assays.  PS and QSH (red) images are shown above.  
Hoechst33258 (blue) is the nuclear stain. QSH shows no saturability for all time points from 0 to 
24 hours.  PS shows saturable uptake around 2 hours.   
 
Interestingly, with the optimized rate of degradation kdeg, the model predicted the concentration of 
QSH degraded (nM), and when converted to Cd2+, predicted absolute cadmium content that fits 
very closely to measured Cd2+ release from QSH under lysosomal conditions (Fig. 4b). This 
further illustrates our model’s predictive power to quantify NM degradation when used in 
conjunction with the RCF assay. For the PS NM, Figure 4c shows the model fit to measured data.  
Subcellular level analysis (Fig. 4d) shows remarkable differences for both NM types. QSH 
membrane quantities were initially higher, until 12 hours, where internalized quantities dominated 
the total cell space. PS maintained high membrane binding with minimal internalization for all time 
points.  Rate constants (Fig. 4e) indicate that membrane binding is the rate limiting step for QSH, 
while internalization is the rate limiting step for PS.  Confocal microscopy (Fig. 4f) qualitatively 
supports these findings, with saturable uptake for PS within 2 hours and limited saturability for 
QSH with higher internalization.  
 
Overall, NMs can be prone to degradative processes within the cellular environment, which can 
cause fluctuations in fluorescent signal and result in inaccurate representation of tissue level 
delivered dose. This issue has prevented fluorescence from being a useful tool for extracting rate 
kinetics.  Here, we showed that cellular degradative effects are present and accounted for in our 
in-vitro assay and corresponding cell kinetics simulation.  We ran QSH (unstable under biological 
conditions) and PS (polystyrene, stable control) NMs against an aggressive murine liver Hepa1-
6 cell line,(13) and found that the NM prone to degradation (QDs like QSH) exhibited substantial 
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deviations in fluorescence, while PS fluorescence remained constant. Our findings in Figure 4 
showed that degradative factors must be accounted for when aiming to extract rate kinetics for 
translation towards animal studies from in-vitro fluorescence data. However, questions do arise 
when understanding how physicochemistry affects total uptake quantities and must be addressed. 
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CHAPTER III. APPLICATION OF RCF ASSAY TO LIBRARY OF 
COMPOUNDS AND ANALYSIS 
NM physicochemistry strongly affects the uptake and toxic response of cells. There is a need to 
understand and develop correlations between physicochemistry and uptake, as the dose will 
inherently affect the response(75) in live animals.  This structure-activity relationship is important 
for understanding and developing important assumptions for predicting NM uptake from in-vitro 
data.  Research is still in relatively new, as most of the correlative analysis has only been 
performed for metal (iron)-oxide nanoparticles(76). A few recent studies have included libraries 
of at least 109 differently surface-modified iron-oxide nanoparticles and their subsequent 
structural surface ligand correlations with cell uptake(77, 78), but the influence of the core 
composition of a NM cannot be ignored, as evidence shows it is a huge influential factor in cell 
interactions(79).  However, the most sensitive descriptors of physicochemistry found in literature 
so far are lipophilicity(76), size(78) , and charge(79).  Taking this into account, we rapidly 
screened a variety of hydrophilic (water soluble) NMs to understand the influence of size and 
charge on total NM uptake.  Addressing these factors ensures that target cell dose is accurate so 
that proper dose-response modeling lead to correct dose(68) determination.  
 
To understand how size and charge can influence uptake of NMs and potentially track these 
correlations, the RCF assay was used to analyze uptake of NMs with various diameters and 
charges.  Specifically, PS, ZnSe (ZQD), and CdSe (CQD) were used as model systems to 
quantify and understand results from changes in physicochemical parameters.  PS consisted of 
NMs with diameters of 50, 100, and 500nm.  50nm PS particles were also analyzed as 
positively charge (amine functionalized, APS), negatively charged (carboxy-functionalized, 
CPS), and naked (hydroxyl-functionalized, NPS). ZQDs and CQDs both consisted of single 
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diameters of 10 and 30nm, respectively.  10nm ZQDs consisted of a positive, negative, and 
neutral charge and 30nm CQDs consisted of solely carboxy-functionalized motifs on the 
surface. 
Size of particles is an influential factor within a range. 
Overall, CPS with sizes of 50, 100, and 500nm exhibited first order kinetics, with their fraction of 
dose uptake at approximately 0.02-0.06 or 2-6% of dose taken up (Fig. 5).  This implies that 
particles within the range of 50 to approximately 500nm in diameter most likely are taken up by 
a similar uptake process, primarily clathrin or caveolin mediated endocytosis.  This is critical, as 
the first order kinetic assumption implies that the total uptake of NMs is dependent on dose, ie. 
as dose increases the total uptake increases, but the fraction of uptake remains relatively the 
same.  Furthermore, first order rate constants would be an accurate description of this process 
for the next chapter. 
 
Figure 5. Carboxy-functionalized total NP uptake for liver cell line with NP of varying size. 
 
Once particles reach over 500nm in diameter, we believe internalization will proceed via a 
different uptake process, primarily macropinocytosis.  Thus, particles below 500nm in diameter, 
we expect to follow first order kinetics and rate of uptake would be properly described by first 
order rate kinetics.  Carboxy-functionalized ZQDs of 10nm diameter exhibited very minimal 
uptake, with cells only taking up approximately 0.002 or 0.2% of the applied dose (Fig. 5).  
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However, when the size increased to 30nm, carboxy-coated CQDs internalized approximately 
0.06 or 6% of the dose.  Again, this jump in uptake of relative fraction of applied dose is 
described by differences in uptake processes.  Smaller particles are expected to enter the 
cellular environment primarily through pinocytosis (cell drinking) or passive diffusion, which is a 
less aggressive form of uptake.  As the particle size increases (~30nm), the uptake process of 
endocytosis (clathrin or caveolin-mediated) is predominant.  Thus, particles of <=10nm in 
diameter must be analyzed carefully when extrapolating in-vitro uptake results to live animal in-
vivo uptake in cells.  Although these particles all contained carboxy-functionalization, it is 
important to note that the core structure of the material for 10 and 30nm particle types is both a 
different class (metal) and type Zn and Cd, respectively.  These results indicate that particles 
within the 30 to 500nm range, with negative charge, will behave similarly when extrapolating 
total uptake to animal tissue cells.  Particle types less than 30 or larger than 500nm must be 
looked at carefully, as other mechanism of uptake must be addressed, or these particles must 
have rate constants optimized to these particles specifically.   
Charge of particles is the greatest influencer when analyzing total uptake of NM within cells. 
Overall, positively charged particles exhibited a higher fraction of uptake than negatively 
charged particles for both ZQD and PS datasets (Fig 6).  
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Figure 6.  Total cell uptake of NPs of varying size and charge.  
 
 Interestingly, both 50nm and 10nm diameter positively charged APS and ZQD were taken up 
by cells at an average of 0.07 or 7% and 0.03 or 3% uptake, respectively.  This indicates that 
although the particles are similar charge (positive), the optimal 50nm size does cause a 
significant increase in uptake to that of the smaller 10nm particle.  This suggests that size and 
charge work together to influence total uptake.  Comparing particles of like negative charge, 
50nm CPS exhibited about a 10-fold higher uptake than their 10nm counterpart (0.03 or 3% 
versus 0.003 or 0.3%, respectively).  Smaller positively charged particles only exhibited 
approximately 2-fold less uptake than the larger particles of similar charge, while smaller 
negatively charged particles exhibited over 10-fold less uptake than their larger counterpart. 
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This difference suggests that uptake of negative particles is heavily dependent on steric 
hindrance and electrostatic attraction to the cell membrane may cause a significantly greater 
influence and masks the difference in size of the particles.  Neutrally charged 10nm ZQDs 
exhibited similar fraction of dose internalized to that of carboxy, indicating that when particles of 
equal or neutral charge rely more heavily on steric hindrance than the electrostatic effects. 
Nanomaterials predominantly internalized exhibit more degradation. 
Unwashed (CSI and MPE) datasets were analyzed for cell and media-induced degradation for 
all NM types (Fig. 7a-j).  
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Figure 7. Total unwashed NP fluorescence after cell exposure. (a-c) show unwashed fluorescence for ZnSe QDs at 
different dosing scenarios (5-90nM).  (d-h) give unwashed fluorescence intensities for PS of carboxy, amine, and neutrally 
coated types.  (i,j) show unwashed fluorescence for CdSe 30nm QD of neutral (PEG2000) and Carboxy coating.
a b c 
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Overall, all PS particles exhibited no cell or media induced degradation for all types and 
concentrations (Fig. 7d-h, P>0.05).  This is attributed to the intact structure of the polystyrene 
polymer and protection of the fluorescent dye in the core.  CQDs had a differing profile for 
carboxy and neutral (PEG3000) functionalized NMs.  As there was significant internalization 
(~8% of applied dose) for carboxy functionalized CQD after 24 hours, this NM exhibited both 
cell and media-induced degradation (Fig. 7j).  Contrary to COOH functionalized CQD, PEG3000 
neutrally functionalized CQD exhibited no cell-induced degradation primarily because of minimal 
internalization (Fig. 7i, ~0.2% of applied dose).  This directly outlines the balance between 
internalization and cell-induced degradation; as internalization increases, we expect cell-
induced degradation to increase for NMs that may be prone to degradative effects.  ZQD did not 
exhibit any cell induced degradation for all NM types, but did exhibit media-induced degradation 
after 1 hour of exposure (Fig. 7a-c).  This scenario outlines the direct effects of media-induced 
degradation for NMs that are not subject to cell-induced degradation.   
Overall, these studies were critical in order to say that assumptions of first order kinetics were 
valid for NMs of similar charge and size.  First, size can be an influential factor when 
understanding cell kinetics.  For NMs <30nm in diameter, the uptake kinetics may be drastically 
different than those within the 30-500nm range.  Likewise, for NMs larger than 500nm in diameter, 
optimization of rate kinetics may be essential for translation to animal studies.  Finally, as dose 
studies suggested, regardless of applied dose, the majority of the NMs exhibited first order 
kinetics so we accept the first order description of the cell model.  That is, similar fractions of dose 
were taken up, regardless of applied dose.  Thus, they exhibited a very strong dose-dependent 
uptake values.  This shows that future simulation studies are reasonable correct in assuming first 
order kinetics.  However, we note that cells reach a maximum saturable uptake at approximately 
24 hours and must be accounted for by inclusion of some boundary constraint for studies longer 
33 
 
than 24 hours.  Cell and media-induced degradation can be influential factors, dependent on the 
material type being studied.  Particles between 30-500nm in diameter can be assumed to behave 
according to similar rate kinetics as long as the charge is within reasonable range.  Differences in 
charge (such as positive and negative) will drastically affect uptake kinetics, so extraction of rate 
kinetics for negatively charged particles will be used for negatively charged particle datasets in 
live animal validation. 
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CHAPTER IV. ANIMAL SIMULATION CONSTRUCTION AND 
FUNCTIONS 
Simulation architecture, particle transport, and tissue content overview 
The overall architecture of the animal simulation can be seen in Figure 8, where each tissue 
compartment contains 4 sub-compartments (epithelial, endothelial, interstitial, and 
macrophage).
 
Figure 8. An overall schematic of the animal NM simulation.  Scheme of the overall tissue 
and blood compartments that make up the full animal.  Each tissue compartment is 
interconnected through blood flow rates and contains sub-compartments (zoomed in area) 
where a NM will distribute upon internalization through endothelial fenestrae.   
Overall, we assume a NM to be 100% bioavailable, meaning it is injected immediately into the 
blood supply (arterial blood) of the pre-clinical species.  Upon entering the blood supply, the NM 
is assumed to be delivered to each tissue type given its tissue specific blood flow rate (Q, Fig. 
8).  Each tissue for every pre-clinical species contains a total tissue volume and blood flow rate, 
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measured empirically and obtained from literature (80).  Tissue volumes and blood flow rates 
were kept as constants throughout the simulation.  Tissue cell compositions (epithelial, 
endothelial, interstitial, and macrophage) and vascular fenestrations were obtained from 
literature, as stated below in this chapter.  Maximum capacities of uptake from our in-vitro 
studies were extrapolated to whole tissues based on cellular content.  All volumes, flow rates, 
and tissue cell compositions were taken relative to the species-specific tissue mass used in the 
study and extrapolated across species as necessary.  Cell densities obtained from literature 
were assumed, for purposes of this study, to be similar across species (cells/g tissue).  We 
understand that tissue cell compositions and densities may vary slightly across species, but for 
demonstration purposes of this pilot study, we assume densities to be consistent.  
 
Particle transport from the blood supply to the tissue interstitia involves calculation of a new 
variable that captures reflection from pore walls, known as a reflection coefficient, explained 
below.  In order for a NM to transport to the interstitia of a certain tissue, we assumed it travels 
through the fenestrations unique to the capillaries of that particular tissue (Fig. 9, inset), each 
with variable sizes found in literature, as explained further below.  These fenestrations were 
represented by reflection coefficients (σv) computed herein to include the effects of particle drag 
and frictional hindrance(81) (Fig. 9a) akin to that of a sphere through an artificial porous 
membrane(82).   
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Figure 9. NM transport from blood supply to cell environment overview. a, Paracellular transport of NM through the 
endothelial fenestrae.  Frictional hindrance and drag force are considered when calculating for the reflection coefficient, which 
is performed for each tissue type.  b, Schematic of the NM transport process through the endothelial lining into the interstitial 
space from where it will interact with tissue cells through rate constants. c, Diagram of NM transport from blood to interstitia 
through the reflection coefficient and from interstitia to the cell environment through rate constants determined from RCF in-
vitro where kx represents the rate constant for a particular process for x = ad, des, int, or deg. 
a 
b 
c 
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A NM located within tissues can accumulate inside the interstitia, vasculature, or within variable 
cell types.  To account for accumulation within variable cell types in this complex architecture, 
in-vitro cellular kinetics (rate constants) were translated to our in-silico animal simulation and 
used as constants when quantifying averaged individual tissue cell interactions.  To determine 
the quality of the rate constants and simulation resolution, we conducted two pilot studies in the 
next chapter, where we 1) assessed trends in whole-tissue uptake as a function of size and 2) 
quantified NM uptake at the single cell level.  The calculated vascular reflection coefficient was 
then held as a constant in a series of ordinary differential equations representing mass transfer 
kinetics from the blood supply to interstitial space where the NM will react with tissue cells (Fig. 
9b, rate constants in red) through first rate constants optimized to our in-vitro data.  The overall 
transport processes involved in a tissue unit are captured in Figure 9c. 
NM transport from blood to interstitia with fluid dynamic model 
The transport of a nanoparticle from the blood supply to the tissue cells is simulated through 
fluid dynamic theory, primarily obtained from a hydrodynamic simulation of solutes through 
pores captured by modeling a reflection coefficient, 𝜎, originally derived by Curry in 1974(81).   
The published and validated fluid dynamic approach is folded in the animal simulation to provide 
predictive, mechanistic method of transport of any NM from the blood supply through pores 
located within an impenetrable membrane to the tissues.  Any nanoparticle with a particular size 
can be predicted to enter all tissues of the body based on transport through capillary pores of 
these tissues.  In theory, a nanoparticle must travel through a pore to enter the interstitial space 
of a particular tissue.  Upon encountering a pore, a nanoparticle cannot occupy positions 
smaller than 1 NM radius from the pore’s edge in blood vessel fenestrae. Thus, NM entry 
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through pores become sterically restricted as the NM approaches the size of the pore(83).  This 
effect is described by the solute partition coefficient (∅) below: 
∅ =
𝜋(𝑟𝑝−𝑟𝑠)
2
𝜋𝑟𝑝
2            (5) 
where rp is the radius of the pore, rs is the radius of the sphere or NM.  These variables are 
reduced to obtain the relation 
∅ = (1 − 𝛼)2           (6) 
where 
𝛼 =
𝑟𝑠
𝑟𝑝
            (7) 
Thus,  𝛼 is the ratio of solute radius to pore radius.  The partition coefficient above is the ratio of 
the area available to the solute to the total pore surface area, accounting for the steric hindrance 
the particle has upon entering the pores of the fenestrae in blood vessels.  However, the particle 
experiences a frictional hindrance from the pore walls upon entering.  The frictional hindrance 
factor F(α) is a factor that defines this phenomena, capturing reduction in diffusion due to 
hindrance that the wall exerts on the particle through the viscosity of the fluid and is captured 
through equation below:  
𝐹′(𝛼) =
(1−𝛼2)
3
2∅
1+0.2𝛼2(1−𝛼2)16
          (8) 
Additionally, the difference between the solute velocity and water velocity (drag force) is 
captured through the hydrodynamic function G(α) according to equation below. 
𝐺′(𝛼) =
1−
2𝛼2
3
−0.20217𝛼5
1−0.75851𝛼5
− 0.0431[1 − (1 − 𝛼10)]      (9) 
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The reflection coefficient accounts for the hydrodynamics of convection and diffusion of hard 
spheres within a right cylindrical pore.  The reflection coefficient is independent of the number of 
channels.  When the reflection coefficient approaches 0, the nanoparticle enters the pathways in 
the membrane.  When it is approaching 1, the pore excludes the nanoparticle and it remains 
outside the pores. The equation for the reflection coefficient accounts for both the frictional force 
and drag, equation below:  
𝜎 = 1 − [1 − (1 − ∅)2]𝐺′(𝛼) + 2𝛼2∅𝐹′(𝛼)       (10) 
The above equation for the reflection coefficient builds on previous studies including Bungay 
and Brenner, Lightfoot et al., and of Lewellen where they accounted for full hydrodynamics 
including steric exclusion, hindrances to diffusion, drag, and pressure drop across the sphere, 
torque and rotation produced by viscous interactions with the wall.  These studies all validated 
the assumptions to measured data for permeability across animal tissue.  This formula assumes 
no interactions between solute particles. 
First order mass transfer kinetics guides particle transport from vasculature and interstitia to cells 
NM transport to cells of a particular tissue is captured through the whole-body NM PBPK 
simulation described herein.  In order for a NM to reach target tissue cells, it must first bypass 
the endothelial cell lining primarily through paracellular transport.  Intracellular transport within 
the endothelial cell population is also captured through rate constants obtained from in-vitro 
RCF rate kinetics.  However, any NM localized within the endothelial cells is either 1) degraded 
or 2) sequestered within the cellular environment.  Intercellular gaps between the cells in-vivo 
are represented by a reflection coefficient, σv.  The reflection coefficient builds on previous 
studies by Bungay and Brenner, Lightfoot et al., and Lewellen where hydrodynamic transport is 
captured, which includes steric exclusion (ϕ), hindrances to diffusion, drag, and pressure drop 
40 
 
across the sphere (G’(α)), and frictional interactions with the wall (F’(α)) described above.  Using 
this coefficient, we can describe the transport of the NM from the blood vasculature (Cv) to the 
interstitial space (CIS) through equation  
𝑑𝐶𝑣
𝑑𝑡
=
𝑄𝑡∙𝐶𝐿𝑈𝑉
𝑉𝑣
−
(𝑄𝑡−𝑄𝐿)∙𝐶𝑉 
𝑉𝑉
− (1 − 𝜎𝑉) ∙
𝑄𝐿∙𝐶𝑉
𝑉𝑉
− 𝑘𝑎𝑑𝑒𝑛𝑑𝑜 ∙ 𝐶𝑉 +
(𝑘𝑑𝑒𝑠𝑒𝑛𝑑𝑜 ∙𝐴𝑚𝑒𝑚)
𝑉𝑉
    (11) 
Where the tissue blood flow (Qt) and lung NM concentration CLUV serve as inputs to this 
compartment, given that the lung is the primary organ that oxygenates the blood supply for all 
the organs of the animal.  The NM will interact with the endothelial cell membrane (Amem) of that 
tissue’s compartment via the adsorption (kadendo) and desorption (kdesendo) rate constants 
determined from in-vitro data.  The vasculature reflection coefficient (𝜎𝑉) serves as guidance for 
the NM to enter the interstitial space given by 
𝑑𝐶𝐼𝑆
𝑑𝑡
= (1 − 𝜎𝑉) ∙
𝑄𝐿∙𝐶𝑉
𝑉𝐼𝑆
 − 𝑘𝑎𝑑 ∙ 𝐶𝐼𝑆 + 𝑘𝑑𝑒𝑠 ∙ 𝐶𝑚𝑒𝑚      (12) 
Where the individual tissue cells (epithelial and macrophages) will interact with the NM through 
the pre-determined in-vitro rate constants kad and kdes for their cell membranes (Cmem).  The flow 
rate into the interstitial space is set to the lymphatic flow rate and vasculature interstitial volumes 
(VIS) guide the concentration for this compartment. Once the NM enters the tissue cell 
membrane compartment,  
𝑑𝐶𝑚𝑒𝑚
𝑑𝑡
= 𝑘𝑎𝑑 ∙ 𝐶𝐼𝑆 − 𝑘𝑖𝑛𝑡 ∙ 𝐶𝑚𝑒𝑚 − 𝑘𝑑𝑒𝑠 ∙ 𝐶𝑚𝑒𝑚       (13) 
it will desorb via the desorption rate constant (kdes) or be internalized into the cell space via the 
internalization rate constant (kint).  Once inside the cell space, the NM can be thus degraded or 
sequestered within the cellular environment (Ccell). 
𝑑𝐶𝑐𝑒𝑙𝑙
𝑑𝑡
= 𝑘𝑖𝑛𝑡 ∙ 𝐶𝑚𝑒𝑚 − 𝑘𝑑𝑒𝑔 ∙ 𝐶𝑐𝑒𝑙𝑙        (14) 
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All tissue compartments herein are described as a series of differential equations designed to 
solve for concentrations utilizing the MATLAB ODE solver.   
Cellular content of the liver 
The liver epithelial cellular composition (cellularity) was taken from Karin and Sternbeck(84) 
wherein they determined the number of hepatocytes per gram of liver for humans, dogs, rats, 
rabbits, and mice using protein content analysis.  The liver macrophage content were 
understood as Kupffer cells, and obtained by Armbrust and Ramadori through rat liver 
immunofluorescent staining of antibodies EDI and ED2 and checked for phagocytosis(85).  Liver 
endothelial cell content were also obtained through staining and centrifugation analysis of 
immune-phenotyping(86).  All cell content from each study were scaled to either rat, mouse, or 
NHP through scaling of cells/g using volume and densities of liver from measured physiological 
data(80).  Fenestrated blood capillaries of the liver can reach diameters as wide as 280nm for 
rodents and 180nm for humans.  Here, there is a minimal glycocalyx matrix and absence of 
basement membrane, so transport into the liver epithelial tissue is minimally hindered.(87) 
Cellular content of the bone 
Bone marrow epithelial content was obtained from Posel et al. wherein they obtained bone 
marrow from 12-week old male rats.  Femurs and tibiae were harvested, purified, and analyzed 
for bone marrow mononuclear cells (BMNCs) using Ficoll-Paque density gradient centrifugation 
and subsequent flow cytometry.  Epithelial cells here are considered B-cells, CD45+, and 
polymorphonuclear (PMN) cells(88). Macrophages are considered CD14+, and CD45+. 
Endothelial cells were taken from Nombela-Arrieta et al. 2017, wherein they used 
immunostaining of mouse bone marrow cells that exhibited CD54-, Ter119-, and CD31+ 
phenotype frequency (%) an compared it to total harvested BMNCs(89). Bone marrow 
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endothelial capillaries of can be sinusoidal, which is an open-pore capillary that is fairly 
discontinuous.  This type of capillary can have a diameter of 30-40um.(90) 
Cellular content of the lungs 
Nine species of animal were studied, with different portions of the alveolar regions of each 
species analyzed.  Cell nuclei were observed from each class of parenchymal lung cell, and 
densities were calculated using electron microscopy.  Number of cells per lung were then 
obtained. Type I and II epithelial tissue cells were then obtained(91).  This was also applied for 
endothelial and macrophage content in the lung.  Endothelial cells lining the luminal area of the 
alveolar regions of the lung are generally connected via tight junctions.  Inter-endothelial 
junctions sometimes contain gap junctions, which have been captured through immune-gold or 
immunofluorescence labeling.  About 27nm gaps appear between plasma membranes of 
endothelial cells have been observed(92) and used in this study. 
Cellular content of the kidneys 
Stereological analysis of total numbers of glomeruli and individual glomerular cell types in rats 
was performed for seven adult rats(93).  Kidneys were perfused and digested and total 
glomerular number was estimated using optical instrumentation and TEM to count cell types.  
Here, we obtained cell types per rat and mouse.  We scaled total number of cells per 
glomerulus using the total number of glomeruli per kidney.  Specifically, we scaled mesangial 
and epithelial podocytes as epithelial and endothelial separately. Macrophage composition was 
taken by Kirkman through rat kidney sectioning and microscopy analysis of multiple kidney 
cross sections, including the cortex, intermedia, and basalis(94). Endothelial pores of the rat 
kidney tissue vary drastically in diameter, from 30 up to 200nm in diameter, as has been 
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measured through scanning electron microscopy imaging(95).  For purposes of our simulation, 
we utilized the upper limits of pore sizes. 
Cellular content of the brain  
Brain epithelial tissue cells (neuronal, and non-neuronal, excluding macrophages and 
endothelial cells) were harvested into a homogenous suspicion of cell nuclei and identified 
immune-cytochemically for rat brain cortex, cerebellum, olfactory bulb, and all remaining 
areas(96).  Brain-specific macrophages (microglia) were analyzed through immunofluorescence 
and flow cytometry in mice, specifically CD11b and CD45(97).  Brain endothelial content was 
taken online through the online mouse atlas obtained from www.mbl.org  funded by the National 
Institute of Mental Health, National Institute on Drug Abuse, and the National Science 
Foundation.  The brain contains a non-sinusoidal non-fenestrated blood capillary, with an inter-
endothelial cell junction opening delineating the physiological upper limit of the endothelial pore 
size, which can be up to 1nm in diameter(87). 
Cellular content of the heart 
Heart endothelial and epithelial cell content were obtained from Pinto et al.(98), specifically, 
epithelial content included cardiomyocytes, fibroblasts, B-cells, T-cells, and other non-
phagocytic or endothelial cell types.  Endothelial cell compositions were obtained here as 
vascular and lymphatic endothelial cells.  Cardiac macrophages were obtained through 
immunostaining and flow cytometry on resident macrophages (99).  The capillaries in the 
atrioventricular node and atrioventricular bundles of various mammals (rats, monkeys, mice, 
cats, and rabbits) were observed by tissue sectioning, where they discovered fenestrations of 
approximately 50nm in diameter, all bridged by a diaphragm.  The non-specialized myocardium, 
however, contains continuous capillaries, so fenestrated capillaries were only found in the 
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conduction system of the heart.(100).  For purposes of our work, we assumed the heart to 
contain fenestrae of approximately 50nm in diameter. 
Cellular content of the small and large intestines 
Total numbers of epithelial cell content for the small and large intestines were taken as the sum 
of total number of epithelial cells in both the crypts and villi of the intestines for rats through 
microscope analysis(101, 102).  Macrophages of the small and large intestines were obtained 
through Lee and colleagues as monocytes per mg of tissue through immunoassay 
procedures(103).  Total capillary volumes were obtained for the small and large intestines and 
the average volume of mammalian cells were used to calculate the number of endothelial cells 
per gram of small and large intestines(104).  Visceral capillaries of the small intestine jejunum 
mucosa contain rounded openings with diameters from 50-80nm in diameter using freeze-dried 
tissue sections of adult rats(105).  The large intestine can contain diaphragmed fenestrae, which 
range between 60-80nm in the intestinal mucosa(87). 
Cellular content of the spleen 
Total splenic epithelial content (splenocytes) were analyzed through immunostaining for a 
mouse and divided by the mass of the average spleen to obtain epithelial cellularity (106).  
Macrophage content were obtained through Lee and colleagues as monocytes per mg of tissue 
through immunoassay procedures(103).  Splenic endothelial content were obtained through 
immunostaining and flow cytometric analysis for total endothelial cells per spleen for mice (107).  
The capillaries of the spleen are sinusoidal, with a deficiency in the basement membrane.  The 
inter-endothelial cell junctions are made up of cuboidal endothelial cells lining the splenic red 
pup located about 2-3um apart(87). 
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Cellular content of the muscle 
Epithelial and endothelial skeletal muscle cells were isolated from the forelimbs and hind-limbs 
of mice through enzymatic digestion and analyzed for immunocytochemistry(108).  Macrophage 
content were analyzed through mouse skeletal muscle immune-histochemical analysis and flow 
cytometry from digested whole muscle.  Here, macrophages were treated as resident 
macrophages(109).  More than 60 cross-sectioned blood capillaries in adult rat skeletal muscles 
were located close to the muscle fibers, with diameters of 60-80nm, closed by a diaphragm at 
the center of the pore(110). 
Cellular content of the skin 
Skin macrophage content were assumed to be Langerhan cells, which make up approximately 
2-8% of epidermal cells in the skin.(111).  From Monteiro-Riviere study and skin cross sectional 
areas and depths, we can estimate the number of epithelial tissue cells per gram of skin(112, 
113).  Skin endothelial cell content were taken from using an average fraction of endothelial 
content for the skin(10), volume of the skin(80), and volumes of a single cell(114).  Rat sub-
epidermal layers of the foot were examined through scanning electron microscope and found to 
have fenestrae with a diameter of 50-60nm in diameter enclosed by a diaphragm(115). 
Animal simulation verification and validation 
After model construction, the full in-vivo model was systematically verified against published 
datasets for primarily the intravenous exposure routes, as this is the first step in predicting 
biodistribution within animal tissue. (13, 80, 116-125).   Consistent with World Health Organization 
(WHO) recommendations(126), our model was validated to ensure that: 
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1. All mathematical errors are fixed so that all equations and parameters are correct 
2. Units are consistent and properly incorporated into all parameters and lines of code 
3. Laws of mass balance are obeyed so that there is no inappropriate loss of compound 
4. Model outputs are devoid of error and model successfully runs with desired outputs 
 
We expected model outputs, if assumptions and simulations exhibited sufficient parsimony, to 
deviate only within a factor of 2, which is the level of adequacy frequently accepted among 
government agencies and pharmaceutical consortiums (127). However, it is expected that some 
level of variation will be observed for tissues not used for specific rate kinetic determination or 
NMs with sizes below 10nm and above 500nm. Uncertainties in the model were also assessed 
through sensitivity analysis for differences in sizes for NMs predicted to enter the tissue interstitial 
space.  In short, this analysis evaluated how the optimized parameters influenced the observed 
model output. We expected and showed that small changes in NM size leads to changes in 
predictions of the dose metric that are less than the variation of experimental measurements. All 
statistical validation was run by comparison of model outputs to in-vivo outputs through mean fold 
error analysis in equation 4 below, 
MFEt = 10 
1
n
∑ log  (FE)
            (15) 
where n is equal to the number of concentration values obtained from a single study for a 
particular time point and FE is equal to the fold error, which is the ratio of the model output and 
observed concentration at time, t.  Overall model tissue output concentrations will be compared 
to observed through log-log analysis.  Specifically, the log of the average of the model outputs 
will be compared to the log of the average of the observed outputs at various time points per 
tissue will be compared on a log-log plot.  If the simulation exhibits very good predictive power, 
47 
 
we expect the simulation to exhibit a good positive correlation (R2) between the predicted and 
observed NM concentrations(27). 
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CHAPTER V.  EXPOSURE OF QD TO CELL TYPES AND RATE 
CONSTANT OPTIMIZATION FOR PREDICTION OF ANIMAL 
BIODISTRIBUTION 
As described in the previous chapter, once a NM has entered and circulated through the animal 
blood supply and entered the tissue environment, it will interact with tissue cells via adsorption, 
desorption, and internalization, all primarily active uptake processes (128).  This interaction with 
cells is critical and needs to be captured in order to assess how much NM has accumulated within 
the animal tissue cell environment.   
Tissue cell rate constants must be obtained for relevant NM and tissue cell types 
For proper extraction of in-vitro rate kinetics and translation to animal simulations, these kinetics 
must be obtained for a NM that exhibits similar physicochemistry to those analyzed in real animal 
studies.  Given that we found no significant difference between uptake of NMs within the 30-
500nm range and there exists no significant differences between NMs of like charge within that 
range, we identified the target physicochemistry as 30nm with a negative zeta potential as a 
reasonable prototype system.  Furthermore, if degradative effects are present, e.g. through 
lysosomal degradation or phase I/II metabolism, we must be sure to understand and capture 
these effects.  Thus, the already validated QSH QD used in chapter II of this work was chosen as 
the NM for rate extraction to animal studies.   
Next, rate constants must be obtained for relevant tissues, i.e. those commonly encountered in-
vivo.  As exhibited in a variety of studies, the liver and kidneys seem to be tissue types with 
substantial NM sequestration, due to their fenestrae sizes within the blood vessels as well as their 
influence on metabolism and excretion of NMs(129) .  Furthermore, the cells that make up the 
mononuclear phagocytic system (MPS) are heavily involved in removal of NMs from the blood 
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supply (monocytes) or tissues (resident macrophages)(130) and should be accounted for.  We 
understand that tissue specific macrophages may be more aggressive e.g. Kupffer cells vs. 
monocytes, but for purposes of this pilot study, we wanted to capture differences between immune 
cells and epithelial/endothelial cells.  Thus, monocytes were chosen as the model system.  Finally, 
given that endothelial cells line the vasculature throughout all tissues and the entire body, we 
considered these cell types    
Thus, to quantify this transport and accumulation within tissue cells and extract rate kinetics for 
animal simulations,  we exposed the previously validated QSH QD to cells commonly 
encountered(131) by NMs upon intravenous injection: macrophages (J774a.1), endothelial 
(C166), and epithelial (liver and kidney, or AML12 and MES13 respectively) cells.  Average tissue 
cell uptake was captured through the previously described cell kinetic assay (Fig. 10A, 
schematic).  
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Figure 10.  In-vitro application of assay using multiple cell types with simulation and rate extraction. a, Fluorescence 
data and assay setup representing unwashed QD fluorescence for unwashed wells that contain kidney(MES13), 
liver(AML12), endothelial(C166), and macrophage(J774a.1) cell types. b Washed raw (black) and calibrated (red) 
fluorescence uptake concentrations (circles, measured) compared to simulation fits (lines) for liver, endothelial, macrophage, 
and kidney cell types. c, Summary of rate constants optimized by the genetic algorithm for model fit to measured datasets. d, 
Time-dependent confocal microscopy images of QD uptake, showing saturation (double-sided arrows) for each cell type in 
the study.  Cartoon is a visual representation of QD-cell interaction kinetics
a 
 
b 
 
c 
 
d 
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Calibrated and raw concentrations for cell types were obtained and use as inputs for in-vitro 
simulation 
Raw signals (ICKD, Fig. 10A) were calibrated for degradative effects through ratiometric analysis 
using equation 1 above. For comparison, raw concentrations were obtained from ICKDt relative to 
the unwashed CSI compartment at time 0 (ICSI0).  These results were entered into a cell kinetic 
simulation to obtain rate constants of averaged NM-cell interactions that are translatable to our 
whole-body (in-vivo) simulation, see below. All data were above the limits of detection (LOD) and 
quantitation (LOQ) with minimal trypsin interference (Appendix A22).    
As Figure 10b indicates, [𝑈𝑝𝑡𝑎𝑘𝑒]𝑐,𝑡 values are considerably higher in macrophages (J774a.1) 
than all other cell types (P<0.05), with macrophages taking up approximately 34% of dose, 
followed by kidney and endothelial (12.59% and 12.56%, respectively), and liver (11.93%) cells.  
This is interesting, as it is commonly observed that macrophages exhibit a more aggressive form 
of uptake, known as phagocytosis. Overall, the assay displayed enough precision to detect 
differences in uptake for tissue types expected to interact with NMs in-vivo.  However, tissue types 
not involved in immune response (epithelial and endothelial) exhibited total uptake within similar 
orders of magnitude, so it is reasonable to extrapolate rate constants from these epithelial tissue 
cells to other epithelial tissue cells in mammalian species for now.  Further studies can be 
performed to incorporate additional cell types in this assay to understand kinetics involved with 
more tissue-specific cell types. 
Cell kinetics simulations were built to use the quantitative data obtained from the assay reported 
here to extract rate kinetics of NM-cell interactions. This cell kinetic model was guided by 
biologically relevant interactions that NMs undergo with cells of a tissue including NM adsorption, 
desorption, internalization, and degradation through fist-order rate constants kads, kdes, kint, and 
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kdeg.  Cells exhibited a saturable uptake profile, with saturation reached at approximately 12-24 
hours.  For extrapolation to animal studies that last longer than 24 hours, we needed to include 
this phenomena.  Consequently, we constrained the adsorption to have a maximum rate of uptake 
when total uptake in cells ([Uptake]t) is zero (0).  As the NM gets taken up by the cells, the rate of 
uptake should decrease as [Uptake]t approaches the maximum capacity of NM uptake for the 
designed study, or Bmax,   included in equation 16 below,  
𝑘𝑎𝑑𝑠  =  𝑘𝑎,𝑚𝑎𝑥 ∗ (1 −
[𝑈𝑝𝑡𝑎𝑘𝑒]𝑡
𝐵𝑚𝑎𝑥
)        (16) 
As total uptake increases, we expect the rate of internalization (kint) to also decrease as [Uptake]t 
approaches Bmax, as shown by equation 17 below, 
𝑘𝑖𝑛𝑡  =  𝑘𝑖𝑚𝑎𝑥 ∗ (1 −
[𝑈𝑝𝑡𝑎𝑘𝑒]𝑡
𝐵𝑚𝑎𝑥
)         (17) 
Eventually, both values (rate of adsorption and internalization) should reach zero as the total 
quantities of [Uptake]t approach Bmax.  These maximum rates of uptake were substituted for kads 
and kdes for later extrapolation to animal simulations. 
All fluorescence based concentration data shown in Figure 10b were used to optimize cell kinetic 
model parameters kads, kdes, kint, (ratiometric calibrated datasets) and kdeg (raw datasets).  At model 
convergence (<100 generations), the optimized parameters provided reasonable average 
correlation coefficients, coefficients of determination, and standard errors (R >0.983, R2 > 0.965, 
and S<0.205nM), respectively, for all calibrated and raw datasets and cell lines with residuals 
randomly distributed around zero (Fig. 10b, insets).  As shown in Figure 10c, the membrane 
adsorption rate constant was highest for macrophages and lowest for endothelial and liver cells.  
This is interesting, as macrophages are generally more aggressive, given their internalization type 
(phagocytosis).  However, the internalization rate was highest for liver tissue cells and lowest for 
endothelial cells.  Overall, each cell type had membrane adsorption as the rate-limiting step.  We 
attribute this phenomena to the like charges exhibited by both the QD and cell membrane surface 
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(negative), so electrostatic repulsion is most likely the phenomena that hinders NM binding to the 
cell surface.  After accumulation on the surface, the QD would then be internalized.  Furthermore, 
all cells exhibited different total NM uptake capacities (Bmax), as shown by their saturable profiles 
after 24 hours of exposure.  Confocal imaging (Fig. 10d) visually supports this data, with rapid 
uptake and saturation by macrophages within 1 hour of exposure, and a more delayed uptake for 
the epithelial and endothelial tissue cells. 
 
Animal simulations are validated at the cellular and tissue level 
Due to the liver and spleen being common targets for NM sequestration, we used these tissues 
as case-studies to understand and capture the sensitivity and accuracy of the simulation’s tissue 
and cellular outputs to changes in NM size(131, 132).  NM reflection coefficient calculation and 
inclusion in the transport mechanism involved within these tissues is briefly shown in Figure 
11a,b.     
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Figure 11. NM transport from blood supply to cell environment validation. a, Paracellular transport of NM through the 
endothelial fenestrae.  Frictional hindrance and drag force are considered when calculating for the reflection coefficient, which 
is performed for each tissue type.  b, Schematic of the NM transport process through the endothelial lining into the interstitial 
space from where it will interact with tissue cells through rate constants. c, Tissue level (liver) simulation predictions for 
variable-sized NMs compared to observed. d,e, Examples (d) of cellular level simulation outputs for variable-sized NMs (e) 
compared to observed splenic macrophage data for validation of rate constants and simulation output. Raw simulated data 
using rate constants with degradative effects (dashed) show increased error >2-fold for 20 and 100nm. 
a 
b 
c 
d 
e 
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Figure 11c shows that a 33 and 83% increase in particle size will produce an increase of 15 and 
37% uptake in total liver tissue.  When compared to observed data, this lies within 2-fold error 
and follows the same observed positive correlative trends between size and uptake.  This 
phenomenon can be explained through the fact that as NM size increases, such that it exceeds 
other tissue pore sizes, the NMs from those tissues should then funnel towards tissues with larger 
pores- in this case, liver.  Variable (20-500nm) diameter biodistribution analysis using Chen 2015 
datasets(132) (Appendix A23) support this principle.  Upon reaching the target tissue, the NM 
will interact with cell populations through rate constants determined in-vitro.  Here, we can see 
that liver endothelial cells (Fig. 11d) have direct exposure to the blood supply, and thus have 
immediate interaction with the NMs at the tissue site, with saturation at approximately 24 hours 
(Alalaiwe study).   As the NM enters the interstitia of the tissue, it quickly interacts with epithelial 
(liver, Alalaiwe study) and macrophage (spleen, Chen study) tissue cells through our in-vitro rate 
constants.  To validate overall model quantification at the single cell level, we used splenic 
macrophage uptake data from the Chen study(132).  When using the in-vitro rate constants 
calibrated for degradative effects, all simulations show accurate predictions (<2-fold error) for 
NMs ranging from 2-500nm in individual macrophages when compared to observed harvested 
splenic macrophages (Fig. 11e).  If simulations used rate constants optimized to raw datasets, all 
simulation predictions would severely under-predict NM uptake in macrophages, leading to >2-
fold error for most outputs (Fig. 11e).  These results build confidence in the predictive power of 
the simulation and capability to predict variable-sized drug content at the single cell level for 
animals for the first time, strictly from in-vitro data.   
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Animal simulation validation across species and NM types 
To build confidence in the simulation’s predictive power and translational capabilities for different 
classes of NMs and species of animals, predictions were compared against measured tissue-
level content for multiple NM types and species.  Complete sets of physiological values (tissue 
volumes and blood flow rates) were obtained for three species including rats, mice, and NHP in 
order to scale cellular content (epithelial, endothelial, macrophage).  The NM animal simulation 
was validated to 15 pre-clinical datasets, which included different dosing scenarios (0.029 - 
64.3mg/kg BW), NM types (polymer, QD, metal, and antibody), and NM sizes (4-197nm 
diameter), all shown in Figure 12a-e. 
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Figure 12. Simulation outputs for validation to various animal studies. a, Tissue-level predicted (line) vs observed 
(points) examples for all species types (rats, mice, and NHP) for visual evidence of model capabilities. b, Heat map of fold-
error analysis calculated for all tissue, NM, and species types in simulation.  Green, yellow, and red represent <2-fold, <3-fold, 
and >3-fold errors.  Fold error was calculated according to equations given in methods section where simulated dataset 
averages were compared to observed.  c, All data point averages specific to tissue types for simulations and observed were 
plotted against each other to yield a linear fit (R2 = 0.861).  d, Tissue-specific fold errors are shown to visualize model 
accuracy for each tissue in this study.  e, NM simulated outputs were ranked (1-4) according to fold-error analysis. 
 
a 
b c 
d 
e 
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As most laboratory biodistribution data only captures total uptake at the tissue level, validation of 
our simulation included total tissue (sum of macrophage, epithelial, endothelial, vascular, and 
interstitial) content.  Evaluations of predictive performance were performed according to world 
health organization guidelines(133) as well as standards accepted by pharmaceutical and 
academic consortiums(134) involved in drug development and safety.  Specifically, 49.78, 33.31, 
and 16.90% of datasets lied within <2-fold, <3-fold, and >3-fold error respectively, demonstrating 
reasonable model performance.  Antibodies(38, 135, 136) exhibited the highest percentage of 
distributions lying within 2-fold error, followed by metal(131, 137-139), polymer(140-143), and 
QD-based(144-147) NMs (Fig. 12e). 
Although assumptions of spherical morphology are not quintessential for antibodies, this 
assumption was practical enough for high model predictivity for this NM.  Just like other materials 
in the nanometer range (~10nm), their distribution properties are also limited by biological 
membranes, so size, charge, and molecular weight will affect their biodistribution(135).  Although 
no metabolic clearance mechanism is included in the simulations yet, 50% of IgG plasma outputs 
lied within 2-fold, 42% within 3-fold and 8% greater than 3-fold error, suggesting good model 
predictivity. Plasma outputs generally under predicted uptake, most likely due to lack of IgG-
endothelial FcRn receptor binding(148), which future in-vitro assays could capture. Simulation 
outputs were slightly overestimated for tissues with high FcRn expression where IgG catabolism 
is prominent(149) (Fig. 12a., skin, muscle, and liver).  IgG catabolism would be a necessary 
improvement in order to correct the simulation over estimation for these tissues (1.70, 2.30, and 
1.42 fold-error over estimate). 
Substantial analysis was performed in major reticuloendothelial system (RES) tissues (liver and 
spleen), each with differing uptake profiles and relative quantities, dependent on tissue 
macrophage content. Overall, simulations mostly fell within 2-fold error of observed values for 
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many of these studies, but generally under predict total tissue content primarily due to 
transcellular transport not being accounted for in our simulation. This effect is prominent for 
simulation outputs for the 25nm CdSe/ZnS QD (liver, Appendix A24) and 4nm CdTe-MPA(147)  
QD datasets for a variety of tissues  (Appendix A25). The 25nm CdSe/ZnS-LM QDs  showed 
accurate (<2-fold error) liver tissue predictions when compared to observed data from live animal 
studies(144), with a larger proportion of uptake in macrophages relative to epithelial cells, as both 
simulation and literature electron microscopy evidence shows (Appendix A24c).  In this case, 
observed data from these studies positively correlates NM accumulation within Kupffer cells to 
minimal biliary or fecal excretion, demonstrating the significance and balance between 
macrophage and epithelial cell interactions with NMs in living systems.  The spleen, with 
approximately 10X more macrophage content than the liver (Appendix A24d), exhibited relatively 
higher percentage macrophage uptake than liver tissue for 28nm PEG5000-Au(138)(mice) 33nm 
PEG2000-SPIO(139) (NHP), 66nm PHEA-SPIO(137), 35nm PEG2000-PAA 44 , and 106nm PS-
PEO(143) NM types (Appendix A24). 
Peripheral tissues like the brain and lungs experienced quick saturation within the first hour, with 
a slight clearance profile most likely due to NM accumulation within tissue vasculature and limited 
permeation through the blood-brain barrier (BBB) and capillary fenestrations (Appendix 
A26)(138-140). Observed TEM evidence supports localization within tissue vasculature and 
simulation data predicts and substantiates this finding(139).   
For studies where metabolism was observed, our simulation either exhibited over estimations or 
did not fit the observed tissue profiles.  Simulations overestimated polymer-based 66nm PHEA-
SPION(137) where biliary and renal clearance were present and failed to match the correct liver 
profile for 112nm PGA(142) where substantial biliary clearance (65% ID) was an influential factor 
(Appendix A27).  Although reasonably matched to observed data (<2-fold error), simulations 
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under predicted liver and kidney uptake of 21nm CdSeS-SiOH QD (Appendix A28).  However, 
study results also show significant fecal/biliary (33%) and urinary (24%) elimination (localization 
within kidney cortex proximal tubules and liver lobules involved in elimination (145)).  In this case, 
transcellular transport and biliary excretion would serve as additional model assistance.  Contrary 
to the 21nm QD, 3.8nm MSA-QD exhibited minimal renal and biliary clearance   (Appendix 
A28c,d) primarily due to considerable QD accumulation within interstitial space (30 min) and 
gradual accumulation within mesangial cells(146) after prolonged periods (Appendix A28e).  
Moreover, electrostatic repulsion from the proteoglycans in the basement membrane of the 
glomerulus fenestrae on the small QD are believed to influence minimal renal elimination, which 
can be addressed through additional computational approaches using surface potential of 
endothelial cell membranes(150) and subsequent(151) repulsion 
Our simulation reasonably predicts biodistribution for PEG2000 and 5000-coated Au, with plasma 
concentrations lying within 1.45 and 1.52 AFE respectively (Appendix A29).  However, our 
simulation does not account for blood half-life as a function of trends in PEG chain length 
(resistance to aggregation by providing minimal protein adsorption), so this effect is not expressed 
in simulation outputs(152) thus far.  We expect, as transcellular transport is included as an 
additional tissue uptake mechanism, NM should escape plasma and enter the tissues thereby 
correcting the 66.67% simulated overestimations.  Plasma profiles for NHP show zero-order 
elimination kinetics (attributed to the NHP glomerular filtration rate or GFR) which our simulation 
does not yet demonstrate and would need to account for in the future.  PGA particles also 
experienced a rapid initial plasma elimination phase (about 50% of ID within 1 hour of exposure 
(Appendix A29), indicating immediate distribution to tissues with large fenestration such as the 
liver and spleen, which is consistent with literature values(142).   
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Overall, NMs between 10 and 100nm diameter (n=65) exhibited the best predictive capabilities 
for our simulation (>50% below 2-fold error for all tissues), most likely due to the fact that 1) 
cellular rate constants obtained in-vitro translated well to the live animal simulation, 2) paracellular 
transport through endothelial fenestrations was the primary means of tissue transport, and 3) 
biliary and/or renal clearance of NM minimally affected biodistribution.  Approximately 50% of 
tissues within datasets containing NMs with diameters <10nm (n=10) lied above 3-fold error and 
40% lie below 2-fold error.  For NMs >100nm in diameter (n=16), the simulation demonstrated 
similar errors within all error ranges (36.43, 25.71, and 37.86% <2, <3, and >3-fold error 
respectively).  Here, we suspect NM size to exceed pore diameter, limiting tissue uptake, so 
transcellular transport would be necessary to fully capture tissue uptake.  Simulated and observed 
datasets were compared through log-analysis of the averages of the datasets and plotted against 
each other, as shown in Figure 12c.  Model predicted averages and observed averages were 
fairly linearly correlated, indicative of reasonable model predictivity across all species and NM 
types (R2=0.861). 
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CHAPTER VI. INNOVATION 
The EPA, FDA, NIH, and NRC have all recognized the need for new tools to assess toxicology of 
nanomaterials. In particular, the involvement of in-vitro cell culture and assays have been called 
for, with in-vitro to in-vivo extrapolation of pharmacokinetic computer models towards hazard 
assessment(62). The combination of in-vitro and in-silico methodologies delivers a solution to 
calculate true effective doses at sites of interest and derive potential dose-response relationships 
that lead to calculated predictive developmental and reproductive toxicity, human safe exposure 
levels, and hazard rankings, all from inputs that translate between in-vitro and in-vivo systems 
and between species for different exposure routes. The innovation in this approach stems from 
the ability to predict cross-species in-vivo target cellular dose from in-vitro data alone, with no 
animal data necessary as inputs.  Moreover, the mechanistic nature of this affords the capability 
to execute potential hazard assessment for any NM type, originating from its consideration of the 
NMs physicochemistry and effects on mechanistic biological processes that determine cellular 
dose at tissues.  Results are obtained in minutes through optimization of software architecture on 
desktop hardware. Key outcomes are rapid screening of nanomaterials and their dose-dependent 
effects toxicity, with benefits for protection of human health starting from a predictive 
understanding of dosimetry at the cellular level in the body. 
Advantages and limitations of the overall method 
Our method makes use of the combined in-vitro assay-simulation approach in a way that is simple 
to apply in the lab. Labs that have cell culture capability and access to a plate reader and computer 
can use the reported method. The major disadvantage of our method is that NMs have to be 
fluorescent. NMs can be made fluorescent with dye coating but it could lead to questions about 
changing the nature of the NM surface, and would require developing proof, if possible, that there 
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is no difference. Materials that degrade fully (or full loss of fluorescence) on the time scale of the 
assay would not work. 
Importance of the method 
NM kinetic data representing interaction with cells is required for accurate predictive modeling of 
NM in-vivo, but has been challenging to deliver to the pharmacokinetic modeling field. With our 
method, these data can be obtained quantitatively. Rate constants optimized to cell uptake data, 
obtained from our method, are valuable in that they may couple directly to in-vivo biodistribution 
modeling. This enables predictive power for NM animal simulations while obtaining biodistribution 
data with cellular level resolution starting from in-vitro assay alone. Tissue level resolution can 
now be enhanced to the cellular level through rate constants determined from the in-vitro portion 
of the RCF method. In the future, this method can provide a streamlined approach to enable much 
quicker and cost-effective NM screening for nanomedicine, public safety, and answering broader 
regulatory questions.  
Future Work and Improvements 
The need for high-throughput screening and predictive analysis is unavoidable given the 
widespread distribution of NMs(153). NMs in these products come with a variety of 
physicochemical properties that affect the manner in which they are exposed to humans.  
Exposure can happen in a variety of ways including inhalation, oral, dermal, and intravenous 
injection, all affecting biodistribution and subsequent target tissue/cellular dose.  In the case of 
inhalation and oral exposure (most common), NMs need to absorb into the blood supply through 
the gastrointestinal (GI) or respiratory tracts, all dependent on their physical properties.  This, in 
turn, affects the systemic distribution of that particular NM, which affects the dose delivered to 
tissue cells.  Moreover, all tissue cells can interact with a particular NM differently, also affecting 
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the exposure dose.  Consequently, this variance in absorption and systematic distribution causes 
huge deviations in toxic response, which complicates the issue of human safety.  This complex 
road map of NM biodistribution must be included in future versions of this work, to account for NM 
sequestration within the respiratory/gastro-intestinal tracts and potential skin lining.   The current 
version of the simulation only accounts for 3 specific cell types- epithelial, endothelial, and 
monocytic, which can be expanded in future versions of this work given the body contains 
substantially more cell types with variations in expression at any given time.  These additional cell 
types can be incorporated in the RCF assay as co-cultures if necessary.  The in-vitro assay 
currently was run for immortalized cell lines, which can be expanded to primary cells if there is 
concern for relevance to live animal physiology, e.g. receptor expression on the cell surface..  
Furthermore, the increase in cell type expression can be included in the animal simulation as a 
changing state variable, given the dosing situation or presence of inflammation.  NMs that exhibit 
targeted effects can be run through this assay, as cell lines overexpressing receptor sites of 
interest can be plated on the 96-well system.  Here, rates of cellular kinetics will then represent 
these targeted effects and can be extrapolated to animal studies. 
Discussion 
A NM injected into the blood supply of a living mammal will not be the dose delivered to individual 
cells of a tissue.  Modern medicine currently has substantial difficulty in assessing dose delivered 
to individual cells due to technological limitations.  Furthermore, optimal NM drug development 
for a particular disease requires a quantitative and accurate understanding of where the drug will 
go, preferably during the early stages of development.  We have advanced these technological 
capabilities through a unique bottom-up approach that predicts live animal biodistribution of 
variable NM types for a variety of species from in-vitro data alone, and with cellular resolution.   
This combination of in-vitro and in-silico methods is expected to help assist for future smart drug 
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design and can be a platform to help scientists make better informed decisions while reducing 
live animal testing. 
Our reported work expands on extensive simulation work between drug design and biodistribution 
for conventional small molecule-based drugs to inform early and proper dosing scenarios for 
effective treatment.  More recent NM simulations have begun to model biodistribution in animals, 
but often fit tissue and blood partition coefficients to animal data in order to describe equilibrium 
partitioning between the two phases. Substantial work has been done to improve on this(40, 41), 
but limitations in tracking mechanistic transport from vasculature to cells and the subsequent cell 
interactions still remained. Our work makes significant advances through the implementation of a 
mechanistic fluid dynamic simulation coupled with in-vitro cell interaction kinetics to provide a 
much higher resolution of NM quantitation. 
NMs sequestered in the interstitia of a tissue alone may not have a therapeutic or toxic effect on 
the cells, so it is critical to track cell uptake phenomena.  As we can see from our simulation 
results, epithelial tissue cells require substantial time to internalize drug, sometimes up to 48 
hours.  In some cases, only 0.94% of the total tissue dose will be located within the epithelial cells, 
so for example, even though the liver would have taken up 14.0% of the injected intravenous dose 
only a small portion will have actually reached the tissue cells. In this case, perhaps the scientist 
may want to increase the injected dose, change the size of the NM, or completely alter the surface 
chemistry and run in-vitro simulations again to obtain higher rate constants.  This is important as 
well in understanding unintended sequestration of NM in peripheral organs.  For example, 
because the body is a working system, the other tissues, like the kidney, may also take up 
particles and lead to inadvertent build-up and possible toxic response.  By virtue of the simulation 
outputs, a scientist can minimize this risk by being able to predict and address these issues. 
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Our implementation of variable reflection coefficients affords the capability to quantitatively track 
the differing NMs in variable tissue types from the blood supply.  This gives valuable insight into 
how effective NM may be in going from blood to tissue.  Additionally, diseased states as well as 
alterations in vasculature endothelial growth factors (VEGF) can alter fenestration development 
and expression, so this advances understanding in quantifying these phenomena.  Although this 
flexibility is critical, we currently assume the NM as a perfect sphere traveling through a cylindrical 
pore.  Biologics like antibodies may not follow this assumption completely, but the assumption is 
parsimonious enough to reasonably predict the distribution within tissues.  Even with the overall 
small error we found in the model predictions, the simulations generally under-predicted the total 
tissue content.  This can be addressed through future inclusion of transcellular transport of 
materials through the endothelial cell lining.  When this effect is accounted for, we expect the 
simulations to increase predictions and match observed total tissue content. 
Future work is necessary to truly consider all mechanistic processes within whole-body 
simulations. Processes like antibody catabolism, metabolic (phase I and II) breakdown and 
clearance of NMs, and transcellular transport of NMs through the vascular lining will need to be 
included in order to provide additional model flexibility and predictive power.  Differences in 
physicochemistry like charge and lipophilicity will affect transport through the vasculature lining 
and may need to be accounted for, which can be captured through correlations between structure 
to biological activity (QSAR). Our study provides a substantial leap forward in predictively tracking 
and quantifying NM transport in live animal tissues starting from in-vitro data alone.  
In summary, the in-vitro concentration data from our ratiometric assay coupled with our cell 
kinetics simulation delivers rate constants for cell-NM interaction that show excellent translatability 
to our mechanistic predictive in-silico whole-body animal simulation. We have also shown that the 
process works under conditions where the NM experience degradation by the biological 
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environment. Thus, we have demonstrated a viable platform for reduction, refinement, or 
replacement of animal testing for NM development. 
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CHATER VII. METHODS AND MATERIALS 
Commercially available quantum dot QSH (negatively charged CdSe/ZnS core-shell), and 
functionalized polystyrene nanoparticles (PS) were purchased from Ocean NanoTech, LLC and 
Magsphere, Inc, respectively.  All materials were used as-is, unless otherwise specified in main 
text.  
In-vitro Statistical Analysis 
Statistical analysis was performed on Microsoft Excel 2010.  All calculated statistical evaluations 
were performed using the student’s two-tailed t-test at the P<0.05, P<0.01, or P<0.001 level. 
Processing and Reading In-vitro Assay in RCF Approach 
All fluorescence measurements were taken with a top-read Tecan M200 Pro Plate Reader.  
Fluorescence for QSH was taken with excitation of 580nm and emission of 620nm. PS was 
excited at 525nm and emission was collected at 595nm.  Zn-based quantum dots were excited 
at 300nm and fluorescence was obtained at 600nm wavelengths.  All plate reader 
measurements were performed using four reads per well to obtain statistically relevant data. For 
compartments CSI, CKD, and controls, 100uL of a 347,000 cells/mL cell suspension (Hepa1-6, 
murine hepatoma, C166 murine endothelial, MES13 murine kidney mesangial, AML12 murine 
liver epithelial, and J774a.1 murine monocyte cell lines from ATCC) were applied and incubated 
for 48 hours in a black 96 well plate (96 well solid black flat bottom polystyrene TC-treated 
microplates, Corning) to allow for 80-90% confluence. At time of experiment, all compartments 
were washed 1X with complete growth media, aspirated, and 100uL aliquots the nanomolar-
specified concentration for all NM types in DMEM (DMEM/Ham's F-12 50/50 Mix, Corning) 
supplemented with 10%FBS (Regular heat-inactivated, Corning) for all compartments (CSI, 
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MPE, and CKD) in plates designated for that particular NM type.  For QSH validation studies, 
each well plate consisted of 18 replicates of each compartment, specifically CSI, MPE, CKD, 
and controls (CC) for 0, .5, 1, 2, 4, 6, 12, and 24 hours. For other NMs where validation was not 
necessary, one triplicate for MPE, CSI, and control was used, but with 1 triplicate designated for 
each time point for CKD. In both scenarios for NMs, at each time point, CKD wells were washed 
2X with complete growth medium, 1X with PBS (Phosphate buffered saline, ThermoFisher 
Scientific), and trypsinized for 15 minutes (0.25% in EDTA, Invitrogen), mixed, and fluorescent 
plate readings run on all well types (CSI, MPE, CKD, and control) with an excitation specified for 
each NM.  All fluorescence values were corrected for media and trypsin background signal.  
Specifically, ICSIt, IMPEt, ICKDt, were all read at these time points.  Icdeg,t and Imdeg,t were taken as the 
difference of IMPEt and ICSIt as well as IMPE,0 and IMPEt, respectively.  Note: 0 hours consisted of an 
entire 96-well plate with aspiration immediately (<2 minutes) after application to all wells and 
subsequent washing and trypsinization of CKD.  Fluorescent plate readings took approximately 
2-5 minutes per plate.   
RCF Parameter Outputs and Usage 
Signals obtained from RCF assay include:  
ICSI,0  
ICSI,t 
IMPE,0 
IMPE,t  
ICKDt 
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Overall, raw fluorescence descriptive of cell uptake (ICKD,t) was taken relative to raw 
fluorescence of unwashed cells at time t (ICSI,t) to obtain a calibrated fraction of uptake (fcell,c): 
𝑓𝑐𝑒𝑙𝑙,𝑐 =
𝐼𝐶𝐾𝐷𝑡
𝐼𝐶𝑆𝐼𝑡
           (18) 
Raw fluorescence descriptive of cell uptake (ICKD,t) was also taken relative to raw fluorescence 
of unwashed cells at time 0 (ICSI,0) to obtain a raw fraction of uptake (fcell,r): 
𝑓𝑐𝑒𝑙𝑙,𝑟 =
𝐼𝐶𝐾𝐷𝑡
𝐼𝐶𝑆𝐼0
           (19) 
These two fractions were then used to obtain concentration of NM uptake using the general 
equation, 
[𝑈𝑝𝑡𝑎𝑘𝑒]𝑐,𝑡  = 𝑓𝑐𝑒𝑙𝑙,𝑥 ∗ [𝐷𝑜𝑠𝑒]         (20) 
where fcell,x is the fraction of uptake for x = raw or corrected,   [Uptake]t is the concentration of 
NM taken up by cells (nM), and [Dose] is the applied dose in nM. To determine if cell-induced 
degradation is present, a two-tailed t-test was performed between unwashed CSI and MPE 
compartments at time, t, (𝐼𝐶𝑆𝐼𝑡  𝑎𝑛𝑑 𝐼𝑀𝑃𝐸𝑡 , 𝑟𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑣𝑒𝑙𝑦). To determine if media-induced 
degradation is present, a two-tailed t-test was performed between unwashed MPE at time 0 and 
time t.   
Cell-induced degradation (𝐼𝑐𝑑𝑒𝑔𝑡 ) was taken as the difference between unwashed without 
(𝐼𝑀𝑃𝐸𝑡) and with (𝐼𝐶𝑆𝐼𝑡) cell exposure, 
𝐼𝑐𝑑𝑒𝑔𝑡 = 𝐼𝑀𝑃𝐸𝑡 − 𝐼𝐶𝑆𝐼𝑡          (21) 
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If media degradation was present, the intensity of this degradation type was taken as the 
difference between unwashed wells without cell exposure from time 0 to time t. 
𝐼𝑚𝑑𝑒𝑔𝑡 = 𝐼𝑀𝑃𝐸0 − 𝐼𝑀𝑃𝐸𝑡          (22) 
Taken together, the sum of these values equals the total degradation that a NM can undergo for 
the RCF assay (𝐼𝑑𝑒𝑔𝑡): 
𝐼𝑑𝑒𝑔𝑡 = 𝐼𝑐𝑑𝑒𝑔𝑡 + 𝐼𝑚𝑑𝑒𝑔𝑡          (23) 
AAS Sample Preparation 
For AAS validation of the above fluorescence RCF results, 50uL aliquots of aqua regia was 
added to every experimental well (both to unwashed/washed and cells/no cells) and left to 
digest for 10 minutes in incubator.  In this case, every well received equal dilution for proper 
ratiometric quantitation.  At time, homogenized solutions were collected and transferred to 
sealed glass vials for atomic absorption experiments.  Care was made to ensure wells were 
kept at equal dilutions, 150uL of total solvent per well, leading to a theoretical QSH 
concentration of 6.66nM for all unwashed wells. Wells with unknown concentrations (washed 
cells) were diluted equally as wells with known concentrations of QSH.  A Perkin Elmer Analyst 
400 AAS spectrometer was used to analyze cadmium solutions.  A cadmium hollow cathode 
lamp with wavelength of 288.65nm was used to obtain optimal cadmium absorption. Flow rate 
was adjusted to 4mL/min and samples were run in triplicate. A 6-point standard calibration curve 
was constructed with NIST grade Cd(NO3)2 in AR.  Care was taken to ensure that sample 
readings were within the linear dynamic range of the calibration curve and limit of quantitation 
(LOQ) of the instrument.  
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AAS QSH Concentration Determination from Cd 
AAS cadmium concentrations from CKD determined from the utilization of a standardization 
curve containing QSH concentrations of 0.25, 0.50, 1.00, 5.00, 10.00nM, and Cd(NO3)2 
concentrations of 0.25, 0.50, 0.75, 1.00, 2.00, and 4.00mg/L.  The slope of the Cd(NO3)2 curve 
was then used to build a new curve correlating QSH nM concentrations to Cd mg/L 
concentrations.  These values were then used to compare AAS results to those in the RCF 
method. 
Assessment of NM Toxicity 
MTS (CellTiter 96 AQ Non-Radioactive Cell Proliferation, VWR) assay was run to determine 
toxicity of a variety of NMs at different doses (QSH and PS) for optimal NM exposure conditions.  
NMs were applied to cells for a period of 24 hours.  Briefly, cells were seeded in triplicate onto 
wells of a clear flat bottom 96-well plates at a density of 34,700 cells/well and left 24 hours for 
attachment.  At time, media was aspirated, and 100uL of all NM solutions were applied to wells, 
except controls, for a period of 24 hours in 37oc CO2 incubator.  Negative controls were kept in 
media to retain complete viability and positive controls were kept in water for cell death. All NMs 
were diluted in DMEM supplemented with 10%FBS at various doses, ranging from 5nM to 
approximately 250nM. At time, cells were washed 2X with complete growth medium and re-
applied with 100uL of DMEM with 10%FBS.  20uL aliquots of MTS was added and background 
absorbance was captured at 490nm.  Plates were then incubated for 2 hours and absorbance 
checked again.  Sample absorption values were normalized to that of cells exposed to complete 
growth medium. 
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Assessment of QD stability 
To assess what dose of QSH would be optimal for the cell kinetic experiment media stability 
was determined. Time-dependent experimental data was taken for QSH at various 
concentrations. QSH solutions were made in DMEM supplemented with 10% FBS at 
concentrations 2.5, 50, 100, 200, 250, and 300nM.  The solutions were applied in 100uL 
aliquots in triplicate to wells of a 96 well plate and left inside incubator for up to 60 hours.  At 
each time point, fluorescence plate readings were taken with a constant z-optimized focal plane 
of 18181um, the maximum fluorescent signal-noise ratio.  This value was kept constant 
throughout the time-dependent study to understand sedimentation effects.   
Lysosomal Colocalization Studies 
Cells were seeded onto 35mm diameter tissue coated petri dishes (35mm TC-treated culture 
dish, Corning) with 2mL of 347,000 cells/mL solution and left in incubator at 37oC and 5%CO2 
for 24 hours.  Cells were washed 1X with complete growth medium and 2mL of 10nM QSH 
solutions were added.  After 24 hours, petri dishes were removed from incubator and washed 
2X with complete growth media.  Lysotracker Green (DND-26, ThermoFisher Scientific) was 
added at 1uM concentration and confocal images obtained. Lysosomal colocalization studies 
were performed using a spinning-disk confocal imaging system.  Z-stacks were taken at 2um 
step sizes, with a total distance of 40um.    
Cell Kinetic Confocal Microscopy 
For each NM analyzed for uptake, we used confocal microscopy.   At each time point in the 
RCF study, cells were washed 2X, trypsinized, and transferred to 35mm petri dishes containing 
2mL of complete growth medium.  After 24 hours, cells were washed 2X with complete growth 
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medium, and Hoechst33257 was applied.  Cells were then imaged for NM uptake with 20 2um 
step sizes.  
Simulated Lysosomal Buffer Studies 
Cellular lysosomal environment was mimicked to determine stress induced on fluorescence 
through lysosomal material exposure.  The citric acid (, >99.5%, ACS Reagent, Sigma-Aldrich)  
simulated lysosome chelator buffer at pH 2.5-5.0 was created and used as the solvent for QSH 
and PS.  Controls contained pH 7.4 DPBS buffer solutions. More specifically, stock solutions of 
.25 and .19mM solutions of sodium citrate monobasic (Anhydrous, Sigma-Aldrich) and dibasic 
(Sesquihydrate, Sigma-Aldrich), respectively, were made.  Stock solutions of 50mM and 20mM 
citric acid stock solution were made in separate vials as well.  Then 6 solutions of equal 
concentrations of 10nM QSH and PS NM were made in either sodium citrate monobasic/dibasic 
with citric acid .  To achieve desired pH of 2.5, 3.0 3.5, 4.5, or 5.0.  pH was adjusted by 
combination of dibasic or monobasic sodium citrate stock solution with small aliquots of citric 
acid solutions.  For size analysis, Zetasizer (Malvern) DLS measurements were obtained.  Here, 
QSH and PS samples were diluted in-situ in solvents of desired pH and measurements obtained 
immediately after.  Fluorescent plate readings were run in triplicates of 100uL of solutions 
applied to wells of a 96-well plate system.  Fluorescence was taken with 580 or 525 excitation 
and 595 or 620nm emission, respectively for QSH or PS, using a Tecan M200 plate reader. 
To check for Cd2+ core leakage, 10nM QSH and PS were analyzed for fluorescence in PBS, 
water, and simulated lysosomal buffer at pH 2.5, 4.5, and 5.0 at 0 hours and 24 hours exposure.  
For each time point, samples were collected and centrifuged at 15,000xg for 20 minutes through 
an Amicon Ultra 10kDa filter to separate possible cations from QSH.  Filtrate was then analyzed 
for free cadmium content using a PerkinElmer atomic absorption spectrometer with a cadmium 
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hollow cathode lamp with wavelength of 288.65nm. Flow rate was adjusted to 4mL/min and 
samples were run in triplicate.  
Prolonged Cell Exposure Study  
Prolonged exposure to intracellular environment analysis was performed after washing at time, 
t.  Here, QSH or PS washed samples at time, t, were left to incubate to an additional 12-x and 
24-x hours, where x is the time of wash for each particular sample.  At total experimental time of 
12 and 24 hours, previously washed plates  were mixed and measured for fluorescence 
changes from their original time, t.  An example is shown below: 
2 hours wash fluorescence  10 hour post wash (12-2 hours) fluorescence 22 hours post 
wash (24-2 hours) fluorescence 
Importantly, 12 hour washed sample only contained 24-x prolonged cell exposure data and 24 
hour washed sample contains no prolonged exposure, given that cell exposure was only 
allowed for the duration of a total time of 24 hours. 
Calculation of Fluorescent Plate Reader Limit of Detection and Quantitation 
The limits of detection (LOD) and limits of quantitation (LOQ) were calculated from construction 
of an 8-point calibration curve with concentration ranging from 0.10-10 or 15nM for QSH or PS.  
The LOD and LOQ were calculated based on the standard deviation of the response signal of 
the blank and slope of the linear curve through zero, equations below: 
LOD =
3σ
S
            (24) 
LOQ =
10σ
S
           (25) 
76 
 
 
where σ is the standard deviation of the blank (NM suspension in trypsin) and S is the slope of 
the calibration curve.  All readings were performed on a TecanM200 Pro. 
Perkin-Elmer AAS Limit of Detection and Limit of Quantitation 
The Perkin-Elmer AAS limits of detection (LOD) and limits of quantitation (LOQ) were calculated 
from construction of a 6-point calibration curve with concentration ranging from .25-4mg/L.  
Media signal in 33% v/v AR was used as blank for these values.  The LOD and LOQ were 
calculated based on the standard deviation of the response signal of the blank and slope of the 
linear curve through zero, see equations 7-8. 
Analysis of QSH Cadmium Core Leakage In Cell Supernatant 
Cells were plated onto wells of a 96-well plate system at 34,700 cells/well and left to incubate 
for 48 hours.  At time, media was aspirated and 100uL aliquots of 10nM QSH was applied.  
Cells were then placed in incubator for maximum experimental exposure time for 24 hours.  
After 24 hours, fluorescence measurements were taken for QSH with no cell exposure (IMPE,t) 
and with cell exposure (ICSI,t) to show difference in total fluorescence.  All sample supernatant 
was collected separately and transferred to 2mL centrifuge tubes with Amicon Ultra 10K filters.  
Samples were centrifuged according to protocol at 14,000xg for 20 minutes to filter out solvent 
and possible free cadmium.  Filtrate and concentrate were then collected analyzed on AAS for 
cadmium concentration. 
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Extraction, Collection, and Harvest Efficiencies 
Extraction, collection, and harvest efficiencies were performed to ensure accurate and precise 
experimental protocol.  For extraction efficiency, cell kinetic samples were washed 2X with 
complete growth media, trypsinized, digested in-situ and collected for AAS.  In parallel, cells 
were washed 2X with complete growth media, not trypsinized, digested with AR in-situ, and 
collected for AAS.  If full extraction of cadmium from cell interior is happening, both sample sets 
are expected to yield similar results, or close to 1 when normalized.  Harvest efficiency was 
performed by collection of QSH from wells with no cells and wells with cells.  In both cases, AR 
was applied in-situ and samples were collected for AAS.  If full QSH cadmium harvest is 
apparent, then normalized data should yield values close to 1.  Collection efficiency was 
performed by comparison of direct dilution of a separate vial of 10nM QSH to 6.66nM by AR 
application in parallel to QSH in wells with no cells and equal digestion in-situ with aqua regia.  If 
all sample is collected from the wells, then the in-situ AAS values should yield similar results to 
the diluted vial and normalized close to 1. 
In-Vitro Model Global Optimization Setup and Evaluation 
All simulations were performed in MATLAB v2015b.  Parameter optimization was implemented 
with the genetic algorithm (GA) optimization function from the Optimization Toolbox.  
Parameters for estimation included: 
Initial Population: 300  
Population Size: 50 
Generations: 100 
Mutation Rate: Mutation Gaussian 
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Crossover Rate: .80 
Selection Function: Stochastic Uniform 
The genetic algorithm was evaluated using the residual sum squares as the fitness function, 
equation below: 
𝑅𝑆𝑆 = ∑ (𝑦𝑖 − 𝑚𝑖)
2𝑛
𝑖             (26) 
where RSS represents the residual sum of squares from model output (mi) at time (i) to 
measured data (yi) for n time points. Standard error was computed as 
𝑆 =  √
𝑅𝑆𝑆
𝑛
             (27) 
where S is standard error, RSS residual sum of squares, and n is total time points. 
Model output upper and lower bounds were evaluated at the 95% confidence interval through 
𝐶𝐿 (95%) = 𝑀𝑜𝑑𝑒𝑙 𝑂𝑢𝑡𝑝𝑢𝑡 ± 2 ∗ 𝑆         (28) 
where CL(95%) represents 95% confidence limit. 
The GA was run for 100 generations, enough to allow for convergence at a fitness value 
representative of measured data. 
In-vitro quantitation of cellular uptake 
To ensure repeatability, the fluorescence assay was completed approximately 2 months apart 
with a new batch of thawed cells for both NM types (n=2), with reproducible results.  The 
fluorescence assay was built starting from the application of cells on a 96-well plate in 3 
“compartments”: the Cell System Interactions (CSI) compartment (cells + NM (unwashed), 
accounts for cell-induced NM degradation), the Cell Kinetic Data (CKD) compartment (cells + 
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NM (washed), measurement of NM uptake), and the Cell Control (CC) compartment (cells in 
media + no NM (unwashed), control with untreated cells to subtract background signal). The 
Media and Protein Effect (MPE) compartment (no cells + NM in media (unwashed)) accounts for 
media and protein induced degradative effects on the NM in the absence of exposure to cells. 
Note that the CSI and MPE compartments are never washed and therefore maintain the initial 
applied dose of NM (10 nM). The CKD compartment is washed at each time, t, to remove NMs 
that are not cell membrane bound or internalized by cells. Control experiments on blank wells 
showed minimal NM adhesion to the sides and surface of wells, indicating all fluorescence 
should strictly come from NM interacting with cells. For assay development and validation to 
AAS for QSH, we used 18 wells per compartment, which resulted in one 96-well plate per time 
point. For the application of this assay to cell types for rate extraction we used in animal 
simulations, we applied QSH at a dose of 10nM to each compartment in triplicate.  At time of 
application, we allowed cells to reach 90% confluence and establish membrane integrity(72) (48 
hours).   At time zero, the CSI, CKD, and MPE compartments were dosed with 10nM QSH or 
PS (10% FBS DMEM suspension), with one NM type per plate. Comparing (by t-test) the 
fluorescence signal for wells in the CSI compartment at time t with the fluorescence signal from 
wells in the MPE compartment at time t gives insight into cell-induced degradation.  If they are 
statistically different we conclude cell induced NM degradation is present and the quantity of 
fluorescence signal loss due to this effect is determined from the difference of CSI and MPE at 
time t.  Similarly, comparing the fluorescence signal (by t-test) from wells in the MPE 
compartment at time t with respect to MPE at time zero gives a description of media-induced 
degradation. These critical steps guide NM uptake calculations, especially if degradation is 
present.  
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NMs analyzed in animal studies for simulation 
The metal-based particles comprised of PEG2000 (32nm)(131) or 5000-coated Au (28nm)(138)   
and PEG2000 (33nm)(139) or PHEA (66nm)(137) coated SPIO NMs.  Polymer based NMs 
consisted of PAA-PEG2000 (35nm)(140), PLGA (197nm)(141), PGA (112nm)(142), and PS-
PEO (107nm)(143). QD studies varied substantially, as we analyzed hydroxide (CdSeS-SiOH, 
21nm(145)), mercaptoundecanoic acid (CdSe/ZnS-LM, 25nm)(144), mercaptosuccinic acid 
(CdTe/CdS-MSA, 3.8nm(146)), and mercaptoproprionic acid (CdTe-MPA, 4nm(147)) coated 
NMs.    
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APPENDIX A. SUPPLEMENTARY FIGURES 
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Appendix A1. MTS assay data for all NMs included in cell kinetic analysis. (a) QSH (negatively 
charged) and (b) PS.  Negatively charged QSH experienced minimal toxicity for all doses, and 
PS exhibited minimal toxicity at 10nM or below. Positive control contained cells exposed to 
water and negative control contained cells exposed to complete growth media. 
 
 
 
Appendix A2.  QSH stability studies inside incubator at 37oc and 5%CO2. Fluorescent results 
for (a) and (b) indicate the relative stability of QSH at a 10nM concentration, reasonable enough 
to select for further cell kinetic analysis.  Optimized detector Z-plane was kept constant on plate 
reader, as QD presence in the optimized focal plane decreased from sedimentation, 
fluorescence drops.  
a b 
a b 
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Appendix A3. QSH and PS calibration curves.  An 8 point calibration curve was constructed with concentrations of .10, .20, 
.40, .60, .80, 1, 5, 10, and/or 15nM in complete growth media.  The linear dynamic range (LDR, linearity) was noted for 
concentrations as low as .10nM and as high as 10 or 15nM for QSH and PS. These calibration curves were used to calculate 
limits of detection and quantitation for both NM types. 
 
 
 
 
 
 
 
 
 
 
a b 
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Appendix A4. Media Interference Study.  (a) Indicates no significant difference between QSH in growth media (red) and 
trypsin (blue).  Slight difference occurs for QSH in DPBS (black) to that in other media types.  PS (b) showed no significant 
difference between all media types, and substantial stability in DPBS (black), trypsin (red), and growth media (blue). 
  
a b 
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Appendix A5.   Study 1 and 2 QSH RCF degradation and fraction of dose experimental data. Study 1(a-b) and 2 (c-d) 
datasets were formed from results given in Figure 2.  (a,c) Shows raw fluorescent signatures for degradation for both studies. 
These values represent differences in fluorescence for CSIt with MPEt and MPE0 with MPEt for cell and media induce 
degradation, respectively.   (b,d) Contain fcell values, obtained from taking the intensities of CKD compartments relative to that 
of either CSI at time 0 or time t, depending on inclusion of degradation effect.  This value was then taken to obtain [Uptake] 
(nM) QSH concentratios in cells according to equation 1 in main text of paper.  
b a 
c d 
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Appendix A6. Study 1 and 2 PS RCF degradation and fraction of dose experimental data. Study 1(a-b) and 2 (c-d) datasets 
were formed from results given in Figure 2.  (a,c) Shows raw fluorescent signatures for degradation for both studies. These 
values represent differences in fluorescence for CSIt with MPEt and MPE0 with MPEt for cell and media induce degradation, 
a b
 
 
a 
c
 
 
a 
d
 
 
a 
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respectively.   (b,d) Contain fcell values, obtained from taking the intensities of CKD compartments relative to that of either CSI 
at time 0 or time t, depending on inclusion of degradation effect.  This value was then taken to obtain [Uptake] (nM) PS 
concentratios in cells according to equation 1 in main text of paper.  
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Appendix A7.  Prolonged incubation of QSH and PS post-wash at time t.  Here (left), a sample was washed at t hours and 
left inside incubator to determine if prolonged exposure to cellular conditions would degrade fluorescent signal over time.  
Quantum dot QSH, top right, shows significant loss in fluorescence signal after prolonged exposure to cellular environment.  
Polystyrene PS, bottom right, shows a steady maintenance of signal upon exposure to cellular environment hinting at limited 
to no fluorescence sensitivity to intracellular environment. 
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Appendix A8.  Simulated lysosomal buffer QSH degradation experiment. (a) Schematic of process of exposure of 10nM QSH 
to lysosomal buffer and further purification and analysis.  (b) Complete analysis of fluorescence signal after 0 and 24 hours of 
exposure.  For QSH in low pH there was instant decrease in fluorescence with substantial fluorescence loss after 24 hours for 
all pH environments.  All solutions were increased back to physiological pH of 7.4 with limited to no increase in fluorescence, 
which infers irreversible loss of fluorescence signal. (c) Filtrate analysis of all solutions show no significant QSH fluorescence 
b
 
 
a 
a
 
 
a 
c
 
 
a 
d
 
 
a 
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in filtrate after centrifugation, indicative of limited to no intact QSH in filtrate.  (d) However, significant cadmium content 
appears in lysosomal buffers, of pH 2.5, 4.5, and 5.0.  No detectable free cadmium was analyzed in filtrate with QSH 
exposure to DPBS and/or water. 
 
 
 
Appendix A9. Analysis of cell-induced fluorescence degradation upon exposure to cellular environment. (a) Full spectral 
analysis of unwashed wells with and without cell exposure for QSH. Washed cell fluorescence (b) normalized for 6 and 24 
hours shows spectral broadening due to cell-induced degradation.  Here, broadening shows an increase from 6 to 24 hours.  
(c) Diagram of potential mechanisms of cell-induced degradation through lysosomal sequestration with 1 surface degradation, 
a
 
 
a 
b
 
 
a 
c
 
 
a 
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2 lysosomal sequestration, 3 possible cadmium leakage, and 4 fluorescence loss due to decreased pH and chelator 
exposure.  
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Appendix A10.  Physicochemical characterization after exposure to lysosomal conditions.  
Complete DLS size analysis for (a) QSH and (b) PS indicate agglomeration for lower pH values 
for QSH and stability for PS.  (c) Shows significant stability for PS fluorescence at 595nm 
emission for all time points and pHs. (d) Shows instability for QSH signal at 620nm emission at 
all time points for all pHs except physiological 7.4.  (e) Shows pH-dependent stability for PS and 
(f) shows QSH pH-dependent instability for all pHs and time-points.  
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Appendix A11.  Supernatant filtrate analysis for free cadmium detection from cell-induced degradation of QSH.  (a) Indicates 
minimal cell-induced degradation at 0 hours and significant (P<0.05) cell-induced degradation for 24 hours.  To determine if 
free cadmium is present outside the cells, samples (supernatant) were centrifuged and filtrate was analyzed for cadmium 
content in (b).  Here, no significant cadmium content was detected. 
 
 
 
 
 
 
 
 
a
 
 
a 
b
 
 
a 
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Appendix A12. Model output with QSH degraded alongside Cd2+ formation.  (a) Shows model fit to calibrated datasets 
(black) and raw datasets (red).  The difference in concentrations between datasets is described via degradation rate constant, 
kdeg, and provides additional information on concentration of degraded QSH (b, black) and subsequent free cadmium (Cd2+) 
(b, red). The concentration of Cd2+ from the degraded QSH core are not high enough to induce toxicity, as shown in (c) for 
Cd(NO3)2 exposure studies on Hepa1-6 cell line for concentrations ranging from .01-100mg/L Cd2+ for 24 hours.  No 
significant toxicity is apparent for doses less than 10mg/L.  As for QSH, no toxicity is also noted for doses used in this study 
(d). 
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Appendix A13. Merged Study 1 and 2 AAS Results. Study 1(a-c) and Study 2 (d-f) were run separetly approximately one (1) 
month apart.  (a,d) Contain calibration curves used to interpolate cadmium concentration for washed cell samples taken from 
the CKD compartment.(b,e) Show washed cell cadmium content obtained from CKD compartments, in mg/L over the time of 
their respective studies.  These values were then divided by the total CSI to (c,f) to obtain a fractional uptake in cells. 
  
a
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Appendix A14.  Collection efficiency experiment was performed to ensure full extraction of dissolved cadmium in wells.  In 
one case, a triplicate of wells exposed to 10nM QD from the MPE compartment was dissolved in 1/3% v/v aqua regia, while in 
the other, 10nM QSH was dissolved a vial with 1/3% v/v aqua regia.  Both scenarios were then transferred to vials for AAS 
analysis.and measured for cadmium content.  The ratio of MPEt to vials were taken, as the plots indicate [Unwashed No 
Cells] / [QD in vial]..  No significant trends in data were noted, and values ratios remained approximately equal to 1, which 
indicates diluted vials and collected wells were similar in cadmium content.   
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Appendix A15. Extraction efficiency for washed well cadmium content. 2X washed cells from CKDt exposed to trypsin or no 
trypsin with the 10nM QSH dose were all exposed to 1/3 v/v% aqua regia for 10 minutes and transferred to vials for AAS 
analysis.  The ratio of CKD Cd content of non-trypsinized to trypsinized was close to 1, indicative of full cadmium extraction 
from cell interior. 
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Appendix A16.   Harvest efficiency above describes the potential to harvest QSH from the total well when there are cells 
present.  Wells exposed to equal doses of QSH  with and without cells (unwashed) were given equal doses of 1/3 v/v% aqua 
regia for 10 minutes.  AAS was performed and the ratio of unwashed cells to no cells is approximately 1, indicative of full 
cadmium extraction, as well as minimal cellular matrix interference on the AAS instrument. 
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Appendix A17. AAS Calibration curve for LOD and LOQ quantitation and QD Correlation.  (a) 
Cadmium concentrations showing linearity from .25 to 4.0mg/L cadmium. (b) Digested QSH 
ranging from .25 to 10nM QSH concentrations with respective signal show linearity for all 
concentrations shown.  Slopes from (a) and (b) were used to determine correlations between 
QSH and cadmium concentrations (c) for further comparison to RCF datasets. 
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Appendix A18. Standard additions technique compared to conventional external calibration 
method. Comprehensive check on cell matrix interference on AAS signal was performed using 
an internal calibration curve (a) where a 24 hour sample was spiked with increasing 
concentrations of Cd(NO3)2 stock.  The output (internal calibration) from (a) was compared to 
conventional 6-point external calibration curve data in (b) No significant difference exists 
between the two techniques, indicating limited to no cell matrix interference
a
 
 
a 
b
 
 
a 
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Appendix A19. Genetic algorithm output for each generation of optimization process.  (a, b) show the fitness function 
(residual sum of squares) at each generation for (a) PS and (b) QSH.  (a) shows model convergence to optimal solution of k 
values at approximately 25 generations (best fitness).  (b) shows model convergence to optimal solution of k values at 
approximately 20 generations for QSH.  Model search for additional best fit is represented by fluctuations in mean fitness 
a
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(a,b) of population for a given generation (red, peaks).  (c, d) show average distance between vectors of a population of 50 
individuals at a given generation.  As the simulation converges, the distance between vectors decreases. 
 
 
Appendix A20. Model output residuals for QSH raw and calibrated as well as PS data.  Detailed residual analysis is shown 
for each model output difference to a particular measured concentration at time t.  The apparent randomly distributed 
residuals around 0, indicate decent model fit to measured data. 
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Appendix A21. Genetic algorithm output for each generation.  (a) Shows the fitness function (residual sum of squares) at 
each generation for model fit to raw QSH data.  (a) Shows model convergence to optimal solution of k values at 
approximately 10 generations (best fitness). (b) Shows average distance between vectors of a population of 50 individuals at 
a given generation.  As the simulation converges, the distance between vectors decreases.
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Appendix A22. Quality assurance on fluorescence signal obtained from NMs in biological 
solutions. a,b, Fluorescence signal for prolonged periods of time under exposure to complete 
growth media (DMF10), DPBS, and trypsin for (a) QSH and (b) PS.  c,d, Calibration curves 
used to determine the limits of detection (LOD) and quantiation (LOQ) for (c) QSH and (d) PS. 
  
a b 
c d 
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Appendix A23. Cellular analysis of NM uptake in varying tissues for NM with different 
diameters. a-c, Cellular uptake of NMs with diameters of 20, 100, and 500nm for spleen, heart, 
and liver with fenestrae diameters of 5000, 50, and 280nm respectively. Sensitivity analysis of 
incremental changes in NM diameter (24, 32, and 44nm) with subsequent liver cell uptake were 
performed.  All simulated (predicted) outputs are compared to observed data from literature 
cellular datasets.
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Appendix A24. Liver and spleen total and cellular uptake of NM for multiple species and NM types. a, Schematic of 
liver cellular composition which consists of endothelial (EnC), epithelial (EpC), and macrophage (KC) cellular content.  The 
NM from the vasculature must travel through the EnC fenestrae to reach the interstitial space (IS). b, c, Total liver uptake (b) 
and cellular content (c) in rat liver tissue.  d, All tissue cellular content for tissues used in this study.  e NM uptake in spleen 
and liver epithelial and endothelial cells, macrophages, and interstitia for Mouse, NHP, and Rats. 
  
a b c d 
e 
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Appendix A25. Total tissue content for mouse intravenous dosing studies. a-e, Total percent of intravenous dose 
predicted by our group and reported in published live animal studies for (a) Kidney, (b), Lungs, (c) Spleen, (d) Liver, and (e) 
Heart tissue. 
  
a b c 
d e 
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Appendix A26. Brain and lung NM sub-tissue content. a-c, Brain sub-tissue content for (a) 33nm PEG2000-SPIO, (b) 
28nm PEG5000-Au, and (c) 35nm PEG2000-PAA. d-f, Lung sub-tissue content for (d) 33nm PEG200-SPIO, (e) 28nm 
PEG5000-Au, and (f) 35nm PEG2000-PAA. 
a b 
c 
d e f 
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Appendix A27. Analysis of tissues involved in NM metabolism. a-d, Liver and Kidney tissue 
uptake for (a,b) Heavily metabolized 66nm PHEA-SPION and (c,d) Minimally 
metabolized112nm PGA NM. 
b a 
c d 
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Appendix A28. Liver and kidney total NM content for 21 and 3.8nm-sized QDs. a-d, Total 
tissue level NM content for liver and kidney for (a,b) 21nm CdSeS-SiOH QD and (c,d) 3.8nm 
MSA-QD.  e, Cellular and interstitial analysis of the smaller, 3.8nm-sized QD inside kidney 
tissue. 
 
 
Appendix A29. Plasma NM content and correlation PEG chain length as well as liver and 
spleen. a, Plasma uptake data for NMs of varying PEG chain lengths. b, Plasma uptake data 
for NM exhibiting substantial excretion profile. 
a b 
c d 
e 
a 
b 
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APPENDIX B: SUPPLEMENTARY TABLES 
  
112 
 
Table B1. Quantum Dot and Polystyrene Limits of Detection and Quantitation 
Sample ID LOD, nM StDev LOQ, nM StDev 
QSH 0.004833968 3.54583E-05 0.016113226 0.000118194 
PS 0.007989205 3.97261E-05 0.026630684 0.00013242 
 
Table B2. LOD and LOQ Values for PerkinElmer Flame AAS 
Cadmium LOD and LOQ Values ± Standard Deviation 
LOD (mg/L) 0.0207 ± 0.000284   
LOQ (mg/L) 0.0691 ± 0.000950   
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Table B3.  Model Output Statistics to Measured Datasets 
Simulation Type       R P-value R Square Std. Error, nM Residual Sum of Squares, nM 
QSH Model Ratiometric 
Calibrated 0.9944 0.0000 0.9889 0.0152 0.0019 
PS Model 0.9380 0.0006 0.8798 0.0158 0.0020 
QSH Model Raw 0.9471 0.0004 0.8969 0.0212 0.0036 
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